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CHAPTER I 
 
INTRODUCTION 
 
Clostridium difficile is the leading cause of antibiotic associated diarrhea and is 
among the most important of the nosocomial pathogens. Advances in the understanding 
of this bacterium have lagged far behind that of other important human pathogens, 
however. There is a notable lack of information about the factors involved in colonization 
and in the case of the two proteins, toxins A and B (TcdA and TcdB), known to be key 
factors in disease, their roles in pathogenesis and their mechanism of action are still 
unclear. In this work, I present structural and functional analyses of TcdA and TcdB. 
These studies begin to fill some of the critical gaps in our understanding of the 
pathogenic mechanism of these two toxins. 
 
Historical overview 
 
Clostridium difficile was first described in 1935 by Ivan Hall and Elizabeth 
O’Toole (1). The researchers discovered the bacteria while investigating the bacterial 
colonization of the intestinal tracts of normal infants during the first ten days following 
birth. In stools from four out of the ten infants being monitored, they isolated anaerobic, 
slow-growing bacteria that had not been described previously. The authors named the 
bacteria Bacillus difficilis on account of “the unusual difficulty which was encountered in 
its isolation and study.” It would later be renamed Clostridium difficile. 
Hall and O’Toole were surprised to discover that C. difficile was pathogenic 
towards animals. When bacterial culture was injected subcutaneously into rabbits and 
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guinea pigs, the animals developed subcutaneous edema, and most died within a few 
days (1). Similar results were seen when the animals were given sterile filtrates from the 
bacterial culture. Heating abolished the toxicity of the filtrate. Thus, Hall and O’Toole, in 
the first report on C. difficile, showed that it was pathogenic towards animals and that the 
disease process involved the secretion of heat labile toxin(s). Nevertheless, the bacteria 
had been isolated from normal infants, and there was no indication that the presence of 
the bacteria had any deleterious effects on the newborns. A few years later, it was 
shown that oral administration of the toxin containing filtrate to rats and guinea pigs did 
not cause disease, leading to the belief that the toxin(s) could not be taken up within the 
gastrointestinal tract (2). Thus, for the next four decades C. difficile remained a little 
known bacterium that was considered a part of the normal intestinal flora of infants. 
C. difficile’s rise from obscurity began in the 1970s when it was found to be the 
primary cause of pseudomembranous colitis (PMC). PMC is a severe condition 
characterized by inflammation of the colon with the formation of plaques, or 
pseudomembranes, along colonic mucosa. These pseudomembranes are typically a few 
millimeters in diameter and are composed of fibrin, mucin, necrotic epithelial cells, and 
neutrophils. (3,4). PMC had been described as early as 1893, but the causative agent 
was undefined for decades (5). Following the development and use of broad-spectrum 
antibiotics, the number of PMC cases increased dramatically (3). An especially large 
number of reported cases occurred in the 1970s following introduction of clindamycin 
(6,7). With this rise in incidence, the search for the cause of PMC intensified, and by the 
late 1970s there was strong evidence from a number of groups that C. difficile was the 
causative agent (3). Moreover, the toxic components that Hall and O’Toole noted in the 
filtrate of C. difficile were implicated in causing PMC. The toxic components were 
identified as two secreted proteins, toxin A (TcdA) and toxin B (TcdB). 
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Clostridium difficile associated disease 
 
Symptoms 
Although the pathogenicity of C. difficile towards humans was first discovered in 
relation to its ability to cause PMC, it is now known that the manifestations of C. difficile 
colonization can range from asymptomatic carriage, to mild diarrhea, to life-threatening 
conditions such as PMC and toxic megacolon. Collectively, the manifestations of 
disease caused by C. difficile are referred to as C. difficile associated disease (CDAD).  
The most common symptoms associated with infection are mild to moderate 
diarrhea (4). More severe infections result in severe diarrhea with abdominal pain and 
swelling, along with systemic symptoms such as fever, dehydration, malaise, anorexia, 
and nausea. The raised plaques, or pseudomembranes, on the colonic mucosa that are 
hallmarks of PMC may or may not be present. When they are present, the symptoms are 
typically more severe (4). The disease can progress to life-threatening conditions where 
the colonic mucosa and the underlying muscularis propia are severely damaged leading 
to paralytic ileus and a decrease in the colonic muscle tone (8). As a result, there is a 
decrease in diarrhea and the colon can become grossly dilated, a condition known as 
toxic megacolon (4). Although toxic megacolon secondary to C. difficile associated colitis 
is rare (0.3-4% of cases), the mortality rate is staggering, with estimates ranging from 
38-80% (8).  
 
Risk factors and transmission 
A number of risk factors have been implicated in CDAD including: 
immunosuppression, poor nutrition, use of gastric acid suppressants, and an interleukin 
8 (IL-8) polymorphism (9,10). However, the most important factors are age, 
hospitalization, and use of broad-spectrum antibiotics (11). Interestingly, infants are 
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typically not susceptible to disease despite high colonization rates (often over 50%), and 
CDAD is rare in children and young adults (3,12). Individuals over the age of 65 are at 
highest risk of disease, being ~5 times more likely to develop CDAD than those in the 
45-64 age group and more likely to die as a result of the infection (12,13).  
C. difficile can be found in the environment, but it is more commonly encountered 
in health care institutions, where there are large populations of infected and at risk 
individuals. A small percentage (~3%) of the general population is colonized by C. 
difficile, and in most cases transiently (14,15). Hospitalized patients and nursing home 
residents have much higher colonization rates of 10-25 and 4-20%, respectively (15,16).  
C. difficile’s prevalence in health care institutions is due in part to the production 
of hardy spores. Spores are presumably the infectious form of the bacteria, as they are 
prevalent in the environment and are more resistant to the acidic environment of the 
stomach (17). Germination is triggered in the duodenum by bile components including 
glycine and taurocholic acid (17). The mechanisms of sporulation and germination are 
poorly characterized for C. difficile, but the importance of spores in human disease is 
obvious. The spore form of the bacteria is metabolically inert and highly resistant to 
environmental stresses allowing them to persist on surfaces for months or years (18-21). 
The spores can be destroyed by bleaching or autoclaving, but not by commonly used 
disinfectants, antimicrobial soaps, and alcohol-based hand products (22,23). Measures 
to control the spread of C. difficile include the isolation of symptomatic patients, use- 
dedicated equipment and personal protective clothing, and specialized environmental 
cleaning (24). These procedures add considerably to health care costs. 
C. difficile in an opportunistic pathogen which rarely infects healthy individuals 
because the natural intestinal flora provides a strong defense against colonization and 
overgrowth. Individuals with depleted flora as a result of antibiotic treatment, however, 
are at great risk of developing CDAD. Symptoms typically begin during or shortly after 
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treatment with broad-spectrum antibiotics including cephalosporins, penicillins, 
lincosamides, and fluoroquinolones (4,9). It is estimated that 15-25% of cases of 
antibiotic-associated diarrhea are caused by C. difficile (25). 
Pathogenic strains of C. difficile have been identified with resistance to many 
common antibiotics including erythromycin, clindamycin, tetracycline, moxifloxacin (26). 
Sequencing of the C. difficile genome has revealed a large number of putative 
resistance genes. Many of these, including tetracycline and erythromycin resistance 
genes, are located on transposable elements, implicating an important role of horizontal 
gene transfer in acquisition of antimicrobial resistance (27,28). Vancomycin and 
metronidazole are the most commonly used antibiotics in the treatment of C. difficile 
infections. So far, no strains have been isolated that are resistant to vancomycin, but 
reduced susceptibility to metronidazole is emerging (26). These antibiotics are not 
effective against the metabolically inert spores (29).  
 
Epidemiology 
Sohn, et al. have estimated that there are 7 CDAD case patients per 1,000 
admissions in acute care hospitals (30). It should be noted, however, C. difficile burden 
varies dramatically by geographic region, between institutions, and even between wards 
of the same hospital (3,15,30,31). Thus, it is unclear how accurately this estimate 
reflects the true burden of CDAD. A number of groups have calculated the costs accrued 
during a hospital stay by patients with CDAD compared to patients whose stay was not 
complicated by CDAD. These estimates range from $2,000-10,000 in additional costs, a 
38-78% increase over matched case-control patients (32,33). Total costs of C. difficile to 
the US health care system are thought to exceed $3 billion per year (34). 
Although the estimates vary concerning the costs and rates of C. difficile infection 
and disease, it is abundantly clear that there has been a dramatic increase in the 
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number of infections between the late 1990s and mid 2000s. Rates of CDAD more than 
doubled in many localities (35). Moreover, there has been an increase in the severity of 
disease and fatal outcomes (36,37). According to death certificate data, C. difficile 
related deaths in the US rose from 5.7 deaths per million in the population in 1999 to 
23.7 in 2004 (13). In England, the number of death certificates listing C. difficile as the 
primary cause of death rose from 499 to 3,393 between 1999 and 2006, surpassing the 
number of deaths caused by methicillin resistant Staphylococcus aureus (35). This vast 
upsurge in CDAD has been primarily attributed to the emergence of a more virulent 
strain, NAP1/027. The NAP1/027 strain has been reported to have higher production of 
TcdA and TcdB (38), a more cytotoxic form of TcdB (39,40), production of an additional 
toxin (41), higher rates of sporulation (42,43), and increased antibiotic resistance (41). 
The emergence of this new strain underscores the significance of C. difficile as one of 
the most threatening nosocomial pathogens.  
 
Treatment 
Disease typically occurs following a disruption of the natural intestinal flora due to 
the use of broad-spectrum antibiotics. Upon diagnosis of CDAD, use of the offending 
antibiotic is stopped. In the case of mild disease, symptoms often naturally subside and 
no additional treatment is necessary (4,44). In most cases patients are administered 
metronidazole or vancomycin, and symptoms typically begin to resolve within 3 days.  
One of the biggest difficulties in treating CDAD is recurrence of disease after 
antibiotic treatment is halted. It is estimated that 15-35% CDAD patients relapse 
following treatment (44,45). Subsequent recurrences are even more likely. If an 
individual has had two or more episodes, the relapse rate is 33-65% (44,46). The high 
recurrence rates following antibiotic treatment is likely because both vancomycin and 
metronidazole prevent the growth of a large number of bacteria, preventing the 
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reestablishment of the intestinal flora. Metronidazole and vancomycin have even been 
reported to initiate CDAD (45). Following cessation of antibiotic treatment, the 
ecologically unstable colon may be re-colonized by remaining spores, which are 
resistant to the antibiotics, or by re-infection (29,47).  
The FDA has recently approved a third drug, fidaxomycin, for treatment of C. 
difficile, which may reduce the burden of recurrent infections. Fidaxomycin (DificidTM) is a 
minimally absorbed, narrow spectrum antibiotic that has been shown in clinical trials to 
be as effective as vancomycin at treating C. difficile infections. Importantly, because 
fidaxomycin is fairly specific for C. difficile, it does not have such deleterious effects on 
the gut microbiota. In clinical trials the recurrence rates were reduced to 13-16% 
compared with 25-27% for vancomycin treatment, and fidaxomycin is thus a promising 
new treatment option for CDAD. Several other antibiotics including fusidic acid, 
teicoplanin, rifampicin, and bacitracin have been reported to clear infection, but none of 
these are approved for use in treating CDAD (46,48). 
In addition to antibiotics, several alternative treatments exist, and several others 
are under development. Because CDAD typically follows a disruption of the intestinal 
flora, probiotics and bacteriotherapy are of great interest. Saccharomyces boulardii and 
Lactobacillus rhamnosus have been reported to prevent CDAD, but reports are 
inconsistent (49,50). Fecal bacteriotherapy, or stool transplant, has been used with high 
success rates (~90% report no recurrence) but is an unpalatable option and thus unlikely 
to become a commonly used therapy (46). A number of adsorbent resins or polymers 
have also been used to bind toxins before they can bind enterocytes. Thus far, some 
(e.g. Tolevamer) have had moderate efficacy, but they are not as good as current 
antimicrobial treatments (46). Finally, a number of immune strategies targeting TcdA and 
TcdB are being explored including the use of intravenous immunoglobulin and 
vaccination (9,46). Toxoid-based vaccines are currently in phase II clinical trials (51). 
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Disease in animals 
C. difficile has been reported to not only colonize but also cause disease in a 
large number of animals including horses, dogs, hamsters, guinea pigs, ostriches, and 
elephants (52). Symptoms often include diarrhea, but clinical manifestations are variable 
(52). Hamsters have been chosen as the model system of choice for studies of C. 
difficile, because experimental infection of hamsters recapitulates many features of 
human disease (3). Most notably, disease in hamsters can be induced by antibiotic 
treatment. Hamsters sometimes show the same symptoms seen in human CDAD such 
as diarrhea and, in some cases, formation of pseudomembranes similar to those in PMC 
(3). In addition, neonatal hamsters, like human infants, are not susceptible to disease. 
However, damage is caused to a different part of the intestine in hamsters, and disease 
is more severe, typically resulting in death.  
C. difficile is also capable of colonizing important food animals including pigs, 
cattle, and poultry. In neonatal pigs C. difficile is an important cause of enteritis (53). C. 
difficile does not seem to be pathogenic towards poultry or cattle, but notably these 
animals are colonized by many of the same strains that are pathogenic in humans. The 
isolation of C. difficile from retail meats has raised the question of whether C. difficile 
may be transmitted by consumption of spore containing foods (52). Given the ubiquity of 
C. difficile and the relative infrequency of community acquired CDAD, it is unlikely that 
foodborne or zoonotic transmission play important roles in the epidemiology of CDAD. 
Nevertheless, the colonization of food animals by pathogenic strains of C. difficile is 
alarming, considering that many of these animals are raised in confined animal feeding 
operations where antibiotics are often used indiscriminately. These conditions are 
favorable for the generation of strains with increased antibiotic resistance.  
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Virulence factors of C. difficile 
  
 Several factors have been implicated in the virulence of C. difficile including 
adhesins (54), extracellular enzymes (55), a binary toxin (56,57), fimbrae (58), flagella 
(59,60), capsule (58), and a paracrystalline S-layer (27,61). Yet, these factors are poorly 
understood, and in many cases their roles in pathogenesis are highly speculative. 
Because C. difficile has been difficult to manipulate genetically, none of the 
aforementioned virulence factors have been mutated and tested in animal models of 
disease. Nevertheless, two C. difficile proteins clearly stand out as important virulence 
factors, toxins A and B.  
Like many pathogenic Clostridia, C. difficile produces several potent toxins. 
Three have been identified for C. difficile: TcdA, TcdB, and the binary toxin CDTab. 
TcdA and TcdB are 308 and 270 kDa proteins with 49% identity and 63% similarity. 
They belong to a larger family of large clostridial toxins (LCTs) which includes lethal and 
hemorrhagic toxins from C. sordellii (TcsL and TcsH), α-toxin from C. novyi (Tcnα), and 
large cytotoxin from C. perfringens (TpeL) (Table 1). LCTs are homologous toxins that 
inactivate host Rho and Ras family guanosine triphosphatases (GTPase) by 
glucosylation. In C. difficile infections, TcdA and TcdB are secreted into the colon where 
they are cytotoxic and proinflammatory (62). All pathogenic strains of C. difficile that 
have been identified, thus far, produce TcdB; and the majority produce both toxins (63). 
CDTab is an actin-specific ADP-ribosyltransferase that is homologous to iota toxin from 
C. perfringens (56,57). Many pathogenic strains do not produce CDTab (64), and 
researchers have struggled to find an association between production of binary toxin and 
pathogenesis (57,65,66). 
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Table 1-1. Large clostridial toxins 
 
Toxin Species Mol. weight Lethal activity1 Targets 
TcdA difficile 308 kDa 50 ng Rho, Rac, Cdc42, Rap 
TcdB difficile 270 kDa 50 ng Rho, Rac, Cdc42 
TcdB-F2 difficile 270 kDa 50 ng Rac, Ras, Ral, Rap 
TcsH sordellii ~300 kDa3 75 ng Rho, Rac, Cdc42 
TcsL sordellii 270 kDa 5 ng Rac, Ras, Ral, Rap 
Tcnα novyi 250 kDa 5-10 ng Rho, Rac, Cdc42 
TpeL perfringens 191 kDa 16 µg Rac, Ras, Ral, Rap 
 
1 Amounts listed are for one mouse lethal dose (MLD), and were obtained by intraperitoneal 
injection (67,68).  
2 TcdB-F is a variant TcdB produced by the TcdA-TcdB+ strain 1470 (69). 
3 The amino acid sequence for TcsH is unknown. The estimated molecular weight is based on 
SDS-PAGE (70).  
 
 
The C. difficile toxins are chromosomally encoded at two distinct loci (Figure 1-1). 
TcdA and TcdB are chromosomally encoded in a region known as the pathogenicity 
locus. The locus consists of five genes: the toxin-encoding genes, tcdA and tcdB; two 
regulatory genes, tcdC and tcdD (also called tcdR); and a putative holin, tcdE (Figure 1-
1). TcdD is a sigma factor that positively regulates transcription of TcdA and TcdB. 
TcdC, on the other hand, is a negative regulator of toxin expression (71). Interestingly, in 
the hypervirulent NAP1/027 strain there is an 18 base pair deletion in tcdC, which is 
thought to result in a 16-23 fold increase in toxin production (38). TcdE has homology to 
holins, and it has been suggested that this protein may be involved in release of the 
toxins by permeabilization of the bacterial membrane (72). In vitro, expression of TcdA 
and TcdB occurs in stationary phase and correlates with a decline in the levels of TcdC 
and increase in TcdD (73). However, the factors regulating TcdC and TcdD are 
unknown. The expression profile of these proteins in vivo is unclear, but TcdA and TcdB 
can be detected in the stool in patients experiencing symptoms of CDAD. 
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Pathogenicity Locus CDT Locus
tcdD tcdB tcdE tcdA tcdC cdtR cdtA cdtB
 
 
Figure 1-1. Organization of the toxin genes in Clostridium difficile. The large 
clostridial toxin and binary toxin genes are encoded in the chromosome at distant loci. 
The genes encoding TcdA and TcdB are found in a 20 kb pathogenicity locus along with 
genes encoding TcdD and TcdC, which are positive and negative regulators of toxin 
expression, respectively. tcdE encodes a holin-like protein that may be involved in 
release of the toxins. cdtA and cdtB encode the binary toxin genes; cdtR encodes a 
sigma factor that regulates their expression. 
 
 
Roles of TcdA and TcdB in disease 
 
Molecular targets of TcdA and TcdB 
 TcdA and TcdB harbor N-terminal glucosyltransferase domains which, upon 
being delivered into the cell, inactivate small GTPase proteins of the Rho family (Table 
1-1). The Rho family includes the prototypical members RhoA, Rac1, and Cdc42 and 
belongs to the larger superfamily of Ras GTPases. The Rho and Ras family GTPases 
are master regulators of a number of vital cellular processes including cycle progression, 
cell-cell adhesion, cytokinesis, secretion, and maintenance of the cytoskeleton (74,75). 
Thus, it is not surprising that these GTPases are targets of a large number of bacterial 
toxins and effectors (76). 
In an ordinary cell, GTPases cycle between active, GTP-bound and inactive, 
GDP-bound states (Figure 1-2). The cycle is controlled by regulatory molecules including 
guanosine dissociation inhibitors (GDIs), GTPase activating proteins (GAPs), and 
guanine nucleotide exchange factors (GEFs). Upon binding GTP, Rho undergoes a 
conformational change allowing it to interact with several effector molecules (75,76). The 
repertoire of effector molecules is extensive and includes protein and lipid kinases, 
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phophatases, lipases, and scaffolding proteins. The downstream signaling cascades 
induced by activation of these effectors are varied and complex. Most are poorly 
understood. Nevertheless, it is clear that these proteins have key roles in the regulation 
of the cytoskeleton and processes requiring cytoskeletal rearrangements.  
TcdA and TcdB preferentially act on GDP-bound, membrane associated Rho 
(77,78). The toxins inactivate Rho proteins by monoglucosylation of Thr37 (Thr35 of Rac 
and Cdc42) (77,79). The Thr37 residue is located in the switch 1 region and participates 
in Mg2+ and GTP binding (80). This region is involved in binding effectors and regulatory 
molecules and undergoes a significant conformational change upon activation 
(74,76,78). Glucosylated Rho GTPases are no longer able to cycle between the soluble 
and membrane-associated states (78). Both GAP-stimulated hydrolysis and GEF-
stimulated exchange of nucleotides are also blocked (81,82). Most importantly, Rho is 
no longer able to switch into its active conformation and bind many of its effectors and 
therefore, numerous downstream signaling pathways are interrupted (74,76).  
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Figure 1-2. Inhibition of the GTPase cycle by TcdA and TcdB. GTPases (here 
represented by Rho in blue) cycle between active GTP-bound (darker blue) states at the 
plasma membrane and inactive states (lighter blue). The cycle is controlled by regulatory 
proteins (pink) including GDIs, GEFs, and GAPs. GAPs promote the hydrolysis of GTP 
to GDP. GDIs sequester inactive GDP-bound Rho in the cytosol. GEFs promote 
activation of Rho by stimulating exchange of GDP for GTP. Activated Rho binds to 
multiple effectors leading to a variety of downstream effects. Glucosylation of Rho by 
TcdA or TcdB results in an inability to interact with regulatory molecules (1-3), switch into 
the active conformation (4), and bind effector proteins (5). 
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Effects of the toxins on cells 
 Though the Rho GTPases affect many cellular processes, their principle role is the 
regulation of the cytoskeleton. Accordingly, the most notable change in cells treated with 
TcdA or TcdB is the loss of cytoskeletal structure. In cultures of adherent cells, treatment 
with toxin leads to rounding of the cells (Figure 1-3). Cell-rounding is one of the most 
commonly used techniques to characterize the presence and activity of TcdA and TcdB. 
Both toxins induce rounding in a wide range of cell types. The cytopathic potency of the 
toxins does vary between cell lines; however, TcdB is 100-10,000 times more potent 
than TcdA towards most cell types (83-86).  
 
Mock TcdA TcdB
 
 
Figure 1-3: Cytopathic effects of TcdA and TcdB on cultured cells. CHO cells were 
plated in a 96 well cell culture dish at 1,000 cells per well in Dulbecco's modified Eagle's 
medium (DMEM) with 10% fetal bovine serum (FBS). Wells were treated with (A) buffer, 
(B) 0.2 µg TcdA, or (C) 0.2 µg TcdB for 4 hours and visualized by light microscopy. 
 
 
 TcdA and TcdB also cause cells to die. Cell death and cell-rounding are distinct 
events in intoxication (87). To distinguish  between the two events, the cell rounding and 
cell death are sometimes referred to as the cytopathic effect and cytotoxic effect, 
respectively. TcdA and TcdB have been reported to cause death through a number of 
different mechanisms including p53-dependent and p53-independent apoptosis, 
caspase-dependent and caspase-independent apoptosis, as well as necrosis (87-92). It 
  
 14         
is challenging to assimilate these and other data into a cohesive model of how C. difficile 
kills cells. It is apparent from these and other studies that inactivation of Rho proteins 
affects many cell-signaling processes in ways that are deleterious to the cell.  
 TcdA and TcdB have a number of effects on cells that do not necessarily result in 
rounding or death, yet may contribute to pathogenesis. Notably, Rho proteins have been 
demonstrated to have a role in regulation of tight junctions, and the perijunctional actin 
ring (93). Accordingly, inactivation of Rho GTPases by TcdA and TcdB results in the 
disruption of cell-cell junctions (94,95). Toxin stimulated disruption of cell-cell junctions 
likely contributes to the increased epithelial permeability and lumenal fluid accumulation 
associated with CDAD. 
In addition, TcdA and TcdB induce the secretion of cytokines in epithelial and 
immune cells. TcdA has been shown to directly or indirectly induce the production of 
macrophage inflammatory protein 2, substance P, IL-1, IL-6, IL-8, transforming growth 
factor β, tumor necrosis factor, and intestinal secretory factor (95-100). Cytokine 
production in response to TcdB has not been characterized as extensively, but TcdB has 
been shown to induce the production of tumor necrosis factor, IL-1, IL-6, and IL-8 (101). 
IL-8, in particular, is thought to play a pivotal role in C. difficile pathogenesis. IL-8 is 
involved in the recruitment and activation of neutrophils, which are present in high 
amounts at sites of C. difficile associated inflammation. Furthermore, a polymorphism in 
the IL-8 gene has been associated with susceptibility to recurrent CDAD (102).  
 
Putative roles of the two toxins in disease 
 The activities of purified TcdA and TcdB have been investigated in a number of 
different animal models including mice, rats, rabbits, and hamsters. Although the 
manifestations of disease vary in the different animals, in these animal models TcdA 
induces fluid accumulation and inflammation within the intestinal tract, whereas TcdB 
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causes minimal or no intestinal pathology (103-105). In the rabbit ligated ileal loops, for 
example, TcdA induces fluid accumulation with comparable activity to cholera toxin 
(105). Unlike cholera toxin, the toxin also causes extensive tissue damage and the 
accumulated fluid is hemorrhagic (3,105). TcdB has no effect in this assay. Likewise, 
when TcdA and TcdB are given to mice and hamsters intragastrically, TcdA causes 
intestinal hemorrhage, diarrhea, and death, but TcdB has no effect (104). TcdB, is 
however, a potent toxin towards these animals when administered by other routes. 
When given by intraperitoneal injection, TcdA and TcdB are both lethal toxins with 
similar potencies (Table 1-1) (67).  
Based on these early studies TcdA was referred to as the enterotoxin, and TcdB, 
because of its ~1000 fold higher cytopathic potency toward cultured cells, was referred 
to as the cytotoxin. It was proposed that TcdA induced the initial damage in the colon 
where TcdB alone was relatively inert. After TcdA had disrupted the intestinal epithelium, 
TcdB might then access and act on other tissues (3). This model implicated TcdA as the 
key virulence factor in disease and TcdB as, perhaps, an accessory virulence factor. In 
support of this model, Lyerly et al. showed that if TcdB is given to hamsters with 
damaged intestines or together with sublethal doses of TcdA the animals die. 
Furthermore, it was shown that a humoral immune response against TcdA correlated 
with protection from disease both in humans and in animal models (106-109).  
 More recently, a number of pieces of evidence have shown TcdB has a much 
more important role in disease than previously appreciated. Since the 1990s, a number 
of pathogenic strains have been identified that produced TcdB, but not TcdA. These 
TcdA-TcdB+ strains produce the same range of symptoms as TcdA+TcdB+ strains in 
humans, and are pathogenic in animal models (110). Thus TcdA is not essential for 
pathogenesis. To date, no pathogenic TcdA+TcdB- clinical isolates have been identified.  
  
 16         
In addition, there have been reports that while TcdB may not be enterotoxic in 
animal models, it is toxic toward human colonic tissues. Riegler, et al. tested the effects 
of TcdA and TcdB on human colonic explants (111). Electrical resistance across the 
membrane was monitored in Ussing chambers following exposure to TcdA and TcdB. 
Damage to the membrane was confirmed by light, fluorescent, and scanning electron 
microscopy. Riegler, et al. found that TcdB was ~10 times more potent than TcdA at 
disrupting the integrity of the membrane (111). Savidge, et al. have demonstrated the 
toxicity of TcdB in a chimeric mouse model of disease where a human fetal intestinal 
xenograft is transplanted into an immunodeficient mouse (101). When challenged with 
either TcdA or TcdB, the human xenografts exhibited intestinal epithelial cell damage 
with marked necrosis, increased mucosal permeability, and acute mucosal inflammation. 
Elucidating the roles of TcdA and TcdB has been slow partially due to the lack of 
genetic tools for the manipulation of C. difficile (112). In 2009, Lyras et al. reported the 
construction of the first isogenic tcdA and tcdB mutants (113). Clindamycin-treated 
hamsters were challenged with the isogenic strains lacking either toxin. Surprisingly, 
knocking out TcdA seemed to have no effect on the virulence of the strain. Strains 
lacking TcdB, however, were avirulent. Death of the hamster was the only reported 
phenotype, so it is not clear if the TcdA+TcdB- strains had subtler pathological effects. 
Nevertheless, this study indicated that TcdB is the more important virulence factor. 
However, when the same experiments were carried out by another group, TcdA and 
TcdB deficient mutants were both shown to cause death in hamsters (114). This second 
group saw a loss of virulence only when both tcdA and tcdB were disrupted.  
Thus, although TcdA and TcdB have long been accepted as the primary 
virulence factors of Clostridium difficile, the relative importance of these proteins in 
disease remains a matter of ongoing debate. Considering that TcdA and TcdB have 
different properties and that most pathogenic strains produce both toxins, we think it 
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unlikely that these proteins have identical roles. Understanding the nature of these roles 
will require further study. 
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Figure 1-4. TcdA and TcdB primary structure and mechanism of cellular 
intoxication. (A) TcdA and TcdB are homologous AB toxins consisting of four domains. 
The enzymatic A component is an N-terminal glucosyltransferase domain (GTD) (red). 
The B component, involved in delivery of the GTD into the cell, has three identified 
domains: receptor-binding (green), ‘delivery’ or pore-forming (yellow), and autoprotease 
domains (blue). The orange box represents the hydrophobic region of the delivery 
domain that has been proposed to form part of the transmembrane pore (amino acids 
956-1128 of TcdB). (B) The delivery process is divided into four main steps that are 
mediated by each of the four domains. 1) The toxin binds to the surface of the cell and is 
internalized by receptor-mediated endocytosis. 2) Acidification of the endosome triggers 
the formation of a pore through which the GTD is translocated. 3) The GTD is released 
into the cytosol by InsP6 dependent autoproteolysis. 4) The GTD glucosylates Rho-
family GTPases at the cell membrane.  
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TcdA and TcdB structure and mechanism of action 
 
TcdA and TcdB are homologous AB toxins. They can be divided into two 
components: an enzymatic A subunit and a B subunit involved in the delivery of the A 
subunit into the target cell (Figure 1-4). The A subunit is an N-terminal 
glucosyltransferase domain (GTD) that inactivates host Rho proteins by glucosylation. 
Three additional domains (B component) are responsible for delivery of the GTD to the 
cytosol of the host cell. These include a receptor-binding domain (RBD), a ‘delivery’ or 
pore-forming domain, and an autoprotease domain. The cytotoxic mechanism can be 
divided into four steps that are mediated by the four known domains: 1) 
binding/internalization, 2) pore-formation and translocation of the GTD across the 
membrane, 3) release of the GTD by autoproteolysis, and 4) inactivation of host Rho 
proteins by glucosylation (Figure 1-4B). Each of these steps is discussed in greater 
detail below.  
 
Receptor-binding 
The C-terminal RBDs of TcdA and TcdB consist of amino acids 1832-2710 and 
1834-2366, respectively (115). The sequences that make up the domains are highly 
repetitive, consisting of multiple 19-24 amino acid short repeats (SR) and 31 amino acid 
long repeats (LR) (74,116). The TcdA RBD is made up of 32 SRs and 7 interspersed 
LRs (Figure 1-5B). The TcdB RBD is considerably shorter and contains 19 SRs and 4 
LRs. Together these repeats form cell wall binding motifs that bind sugar moieties on the 
surface of host cells (117,118). Cell wall binding motifs from TcdA were initially shown to 
bind α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc (119). However, this sugar is not present on 
human cells (120). TcdA has since been reported to bind to the human I, X, and Y blood 
antigens as well as a human glycosphingolipid (120,121). These molecules all have the 
  
 19         
core β-Gal-(1,4)-β-GlcNAc structure found in α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc. It is not 
know which of these, if any, serve as the native ligand in the human colon.  
Two proteins have been implicated as receptors for TcdA. Rabbit sucrose-
isomaltase was first shown to serve as a receptor for TcdA in the rabbit ileum (122). 
Binding to sucrose-isomaltase was inhibited by galactosidase treatment, indicating that 
the toxin binds the glycosyl modification on the protein, but the identity of these sugars is 
unknown (122). Rabbit sucrose-isomaltase cannot be the only receptor for TcdA, 
because many cells and tissues, including the human colonic epithelium, do not express 
this protein yet are sensitive to TcdA (122). More recently, the human protein gp96 has 
been reported as a receptor for TcdA (123). Like sucrose-isomaltase, gp96 is predicted 
to be glycosylated, but the identities of the saccharides have not been determined. It has 
not been shown for gp96 whether or not the saccharide modifications are involved in 
binding TcdA. No receptors have been described for TcdB.  
In 2005, Ho et al. published the crystal structure of a fragment of TcdA 
comprising amino acids 2573-2709 (TcdA RBD f1) (Figure 1-5A) (pdb 2F6E (115)). This 
fragment contains 4 SRs and 1 LR. The structure revealed that each repeating element 
consists of a β-hairpin followed by a loop. In the SRs, the loops are 7-10 amino acids in 
length, whereas the LR loop comprises 18 amino acids. The SRs are packed together in 
a regular fashion where each repeat is rotated by ~120° in relation to the previous one 
(115). The repetitive stacking of SRs forms straight, rod-like structures. The LR’s 
packing with its adjacent SRs disrupts the regular repeating arrangement of the SRs, 
causing a ~30° kink in the rod-like structure (115). Using the structure of the TcdA RBD 
f1 as a template of SR-SR and SR-LR interactions, Ho, et al. constructed a model of the 
entire TcdA and TcdB RBDs (Figure 1-5C).  
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Figure 1-5. Structure of the TcdA receptor-binding domain. (A) Crystal structure of 
TcdA-RBD fragment 1 (f1), consisting of residues 2573-2709 (115). The structure 
consists of repeating elements that contain a β-hairpin followed by a loop. In short 
repeats (SR), the loops comprise 7-10 amino acids; in long repeats (LR) the loops 
consist of 18 amino acids (LR loop indicated by *). The SRs pack together into relatively 
straight rod-like structures; whereas the LR packing with its adjacent SRs results in a 
~30° kink in the structure. (B) The entire TcdA RBD is made up of 32 SRs with 7 
interspersed LRs, which are represented by green and blue boxes, respectively. The 
TcdB RBD consists of 19 SRs and 4 LRs. (C) Models of the TcdA and TcdB RBDs were 
constructed based on the structure of TcdA RBD f1. The models are colored as in (B). 
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The same group later published a co-crystal structure of a larger fragment (f2) of 
the RBD in complex with an α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc derivative (pdb 2G7C 
(124)). This structure revealed that the saccharides bind at the junctions formed between 
LRs and SRs (Figure 1-6). Thus, each of the kinked regions in Figure 1-5C represents a 
putative saccharide binding side. TcdA has 7 such binding sites, whereas TcdB has 4. 
The model taken from these structures suggests multivalent binding along an extended 
binding domain (124).  
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Figure 1-6. Carbohydrate recognition by the TcdA RBD. (A) The crystal structure of 
TcdA RBD f2 (amino acids 2456-2710) is shown with the SRs colored green and LRs 
colored blue. The head-group of the bound liposaccharide α-Gal-(1,3)-β-Gal-(1,4)-β-
GlcNAcO(CH2)8CO2CH3 is shown in yellow. (B-C) A close-up view of the C-terminal 
trisaccharide-binding pocket formed by an LR and adjacent SR. The electrostatic surface 
potential is shown with negatively-charged surfaces in red and positively-charged 
surfaces in blue (transparent in (B) and opaque in (C)). In (B) residues that make up the 
trisaccharide binding pocket are shown as sticks, and hydrogen bonds are shown as 
dashed lines. The labeled residues are strictly conserved in the saccharide-binding 
repeats of the TcdA RBD, but are divergent in the TcdB RBD. 
 
The binding of α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc is shown in Figure 1-6. The 
terminal α-Gal abuts the large loop of the LR and makes several hydrogen-bonding 
contacts with residues of the loop (e.g. Gln2638) (Figure 1-6B). The central β-Gal moiety 
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sits with its methoxy group pointed down into a small basic cleft formed in part by 
Glu2623. The oxygen of the methoxy group hydrogen bonds with Lys2661 of the SR. 
The GalNAc group interacts with a number of SR residues including a hydrogen bond 
formed with Ser2660. The residues pointed out here (Glu2623, Gln2638, and Ser2660, 
Lys2661) are all strictly conserved in the saccharide binding repeats of the TcdA RBD. 
Yet, these residues are strikingly different in the TcdB RBD repeats. Glu2623, for 
example, which contributes to the small acidic pocket where the β-Gal binds is replaced 
by a bulky, basic residue (lysine) in each of the TcdB LRs. Thus, while the TcdB RBD is 
predicted to have a similar fold to the TcdA RBD, the saccharide binding sites are 
radically different. This provides a likely explanation for why TcdB does not bind the β-
Gal-(1,4)-β-GlcNAc with the affinity of TcdA.  
Many gaps remain in our understanding of the binding of the C. difficile toxins to 
target cells. Chief among these is the identity of the receptors. While there is some 
knowledge of TcdA binding targets, nothing is known about the nature of the TcdB 
receptor. Both TcdA and TcdB act on many cell-types with varying potency in tissue 
culture experiments, but the target cells in vivo are unknown. It is also unknown whether 
or not the carbohydrate-binding repeats are the only parts of the proteins involved in 
binding to cells. The homologous toxin TpeL from C. perfringens lacks the C-terminal 
repeats yet is still toxic, albeit less potent (68). Likewise, removing the RBD from TcdA 
or TcdB attenuates, but does not eliminate cytopathicity suggesting the existence of an 
additional binding activity outside of the RBD (125,126). Finally, it is not known how 
binding induces uptake. TcdA and TcdB were recently shown to be taken in by clathrin-
mediated endocytosis, but the mechanism by which internalization is stimulated has not 
been discovered (127). 
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Pore formation 
Once the toxins have been internalized, the glucosyltransferase must be 
delivered across the endosomal membrane. Based on analogy to many other AB toxins, 
endosomal acidification is thought to induce structural changes in the delivery domain 
that expose hydrophobic segments. These hydrophobic regions insert into the host 
membrane forming a pore through which the glucosyltransferase domain can pass. 
Although this has not been demonstrated for TcdA or TcdB, data from previous studies 
are consistent with this model. 
Qa’dan, et al. have shown that acidification causes structural rearrangements in 
TcdB. The authors demonstrated that upon reduction of pH to 4.0, TcdB exhibits 
differences in native tryptophan fluorescence and protease susceptibility. As expected, 
these changes resulted in the exposure of hydrophobic surfaces as detected using an 
environment-sensitive fluorescent probe (128). Barth et al., have shown that acidification 
not only induces conformational changes, but also triggers pore formation. Chinese 
hamster ovary (CHO) cells were preloaded with 86Rb+, and then treated with TcdB. 
Under acidic conditions, 86Rb+ was released into supernatant when TcdB was present, 
indicating that TcdB inserts into the membrane and forms ion channels. The authors 
further showed that TcdB can induce ion channels in artificial lipid bilayers at low pH 
(129). TcdA has also been shown to form pores in cells and in artificial bilayers (130). 
For TcdA, but not TcdB, cholesterol is essential for pore-formation (130). Barth et al. and 
Qa’dan, et al. further demonstrated that these results are applicable in natural 
intoxication of cells. Treatment of cells with pharmacological inhibitors of endosomal 
acidification (e.g. bafilomycin A1) retards the toxic effects of TcdB, presumably by 
inhibiting pore formation (128,129).  
Within TcdA and TcdB, amino acids ~956-1128 are particularly hydrophobic and 
have been hypothesized to compose at least part of the transmembrane pore (116,118). 
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Genisyuerek, et al. have recently constructed a series of TcdB truncations to delineate 
the region of the toxin responsible for pore-formation (131). Their results indicated that 
the amino acids 830-990 contain the minimal pore-forming region (131). This raises the 
question of what the role of the other 875 residues in the delivery domain is in 
intoxication. It has been suggested that the C-terminal part of the domain may have a 
role in binding to cells, but there is very minimal evidence for this (125,126). So far, 
nothing is known about the structure of the delivery domains of TcdA or TcdB in either 
the soluble or membrane states. It is not even known whether the toxins must 
oligomerize in order to form a pore. Understanding the structural changes that allow 
TcdA or TcdB to go from being soluble proteins to membrane pores is a challenging 
structural problem important for understanding the function of these proteins. 
 
Autoproteolysis 
 LCTs are made and secreted as single polypetide chains. It was unknown for 
many years whether the toxin remained intact or if the A component (GTD) was released 
into the cell as is typical for other AB toxins. It was first shown in 2003 that TcdB is 
proteolytically processed and that only the N-terminal GTD is released into the cytosol 
(132). In 2005, the cleavage site was localized between Leu543 and Gly544, and it was 
revealed that cleavage was mediated by a component of the target cell cytosol (133). It 
was thought that this proteolytic event was mediated by a host protease (133). 
Surprisingly, when Reineke, et al. tried to identify the host factor required for cleavage of 
TcdB, they found that the host factor was not a protein but a small molecule, one of the 
inositol-phosphates (134). The most active of the inositol-phosphates was inositol 
hexakisphosphate (InsP6) (134). When mixed with purified LCTs, InsP6 alone was 
enough to induce cleavage. Reineke, et al. further showed that treatment with 1,2-
epoxy-3(p-nitrophenoxy)propane, a covalent inhibitor of aspartate proteases, modified 
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Asp1665 and inactivated the toxin. Thus, the authors proposed that Asp1665 is the 
catalytic residue of an aspartate activity encoded in the central region of the toxin. 
However, this could not explain InsP6-induced cleavage of Tcnα, which does not have 
an aspartate in this position.  
Just a few months later, Egerer, et al. published a second paper describing the 
autoproteolytic processing of TcdA and TcdB (135). They confirmed that cleavage was 
stimulated by InsP6, and showed that reducing agents enhanced the rate of cleavage. 
The major finding, however, was that cleavage was mediated by a cysteine protease 
domain (CPD) adjacent to the GTD. This finding has been borne out in a number of 
subsequent studies including our own (Chapter II), whereas there have been no further 
reports of aspartate protease activity for any LCT.  
The autoprotease domain was identified based on its homology to a CPD that 
had just been discovered in a large multifunctional autoprocessing toxin (MARTX) from 
Vibrio cholerae (136). As in the LCTs, the V. cholerae MARTX (VcRTx) toxin CPD 
facilitates the release of enzymatic moieties into the target cell, and it is also activated by 
InsP6 (137). In 2008, the structure of the VcRTx CPD bound to InsP6 was published 
(pdb 3EEB (138)). It was shown that InsP6 binds in a basic pocket and allosterically 
activates cleavage at a separate catalytic site containing a catalytic triad of cysteine, 
histidine, and aspartate residues. The TcdA CPD and VcRTx CPD are only 19% 
identical, yet the residues that make up the putative catalytic triad are strictly conserved 
among all LCTs and necessary for InsP6-induced proteolysis of TcdB (135-137,139).  
The discovery of the autoproteolytic processing of LCTs and identification of the 
responsible domain have filled a critical gap in the model of GTD delivery into target 
cells. Moreover, this activity presents a possible new therapeutic target for inhibiting 
toxin action. A deeper understanding of the structural and mechanistic details is an 
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important next step in advancing our understanding of the mechanism by which these 
proteins intoxicate cells. This is the subject of Chapter II of this thesis. 
 
Glucosyltransfer 
The N-termini of the LCTs contain a 63 kDa GTD responsible for cytopathicity 
(140). As discussed previously, once the GTD is translocated into the cytosol it 
inactivates small Rho GTPases by glucosylation of a threonine in the switch region. 
UDP-glucose serves as the source of glucose for TcdA, TcdB, TcsH, and TcsL (77,141). 
The homolog Tcnα, however, uses UDP-GlcNAc (142). TpeL can use either UDP-
glucose or UDP-GlcNAc as the co-substrate (143). 
Based on in vitro experiments, TcdA and TcdB can target RhoA, RhoB, RhoC, 
RhoG, Rac1, Cdc42, and TC10 (74,144). TcdA has also been reported to modify the 
additional substrates Rap1A and Rap2A which are more closely related to Ras family 
proteins (84). TcsH and Tcnα also target Rho family substrates (Table 1-1) (142,145). 
TcsL and TpeL, on the other hand, act mostly on Ras family proteins such as H-Ras, Ral 
and Rap (143). They can also target Rac but not Rho. Like the Rho proteins, the Ras 
GTPases are involved in a large number of cellular signaling pathways. They have 
important roles in the regulation of cell-cell junctions, cell proliferation, and survival 
(146).  
A number of strains have been identified that produce a variant TcdB which 
modifies Ras family substrates (69,147,148). These are sometimes referred to as 
functional hybrids because most of the TcdB protein is the same as in prototypical 
strains (e.g. 630), but the GTD has the substrate recognition properties of TcsL. 
Interestingly, all of the TcdA-TcdB+ strains that have been characterized so far carry 
these variant toxins. It is not known why some toxins preferentially target Rho family 
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proteins while others target Ras family proteins, but it is clear that the inactivation of 
these different proteins has different effects on the cells (69,147-149).  
In 2005, Reinert et al. determined the crystal structure of the GTD of TcdB in 
complex with UDP-glucose (pdb 2BVM (150)). The structures of the GTDs from two 
other LCTs, TcsL and Tcnα, have also been determined (pdb 2VKD and 2VK9 (151)). 
These structures coupled with biochemical data have helped shed some light on the 
enzymatic mechanism of glucosyltransfer.  
The structure of the TcdB GTD is presented in Figure 1-7. At the core of the 
structure is a Rossman fold similar to what is seen in other glycosyltransferases 
belonging to the glycosyltransferase A (GT-A) family (150). In addition to the common 
GT-A family fold, TcdB has a number of α-helical additions (red). These include an N-
terminal 90-residue subdomain at the ‘bottom’ of the GTD, as presented in Figure 1-7A, 
and several other large protuberances at the ‘top right’ and ‘top left’. The N-terminal 
subdomain has recently been shown to target the GTD to the plasma membrane, the 
site of the target GTPases (152,153). This region is, therefore, referred to as the 
membrane localization domain (MLD). The role of the other α-helical additions is 
unknown, but it has been suggested that these residues may be involved in substrate 
binding (150). 
The structure of the TcdB GTD facilitated the identification of important residues 
in the reaction mechanism. In the TcdB GTD structure, UDP-glucose is hydrolyzed into 
UDP and glucose, but both molecules are bound along with the essential cofactor Mn2+. 
As in other GT-A proteins, UDP-glucose is bound in a pocket formed by the edge of the 
β-sheet and several α-helices. A loop consisting of residues 517-523 overlays the 
binding pocket and two residues within this loop (Ser518 and Trp520) are involved in 
binding the phosphate group of UDP (Figure 1-7C). Figure 1-7C shows several other key 
residues that are involved in binding UDP-glucose. The activity of the enzyme is reduced 
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or abolished when these residues are mutated, with the possible exception of Glu515 
and Asn139 which have not been tested (140,154). The structure was also used as a 
platform to discover residues that are involved in binding target GTPases. Jank, et al. 
have found 5 residues (Glu449, Arg455, Asp461, Lys463, and Glu472) that when 
mutated result in loss of substrate modification. These residues are located immediately 
to the ‘left’ of the UDP-glucose binding pocket (cyan in Figure 1-7B). The transferred 
glucose is only accessible from this ‘front’ view of the GTD, thus the GTPases must bind 
to this side of the molecule. A detailed model of substrate binding, however, is lacking. 
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Figure 1-7. Structure of the TcdB glucosyltransferase domain. (A) The core GT-A 
fold is shown in orange, and the α-helical additions are shown in red. The N-terminal 
four-helix bundle makes up the MLD. (B) Surface view of the TcdA-GTD as shown in (A). 
Glu449, Arg455, Asp461, Lys463, and Glu472, residues that have been shown to be 
involved in GTPase binding, are colored cyan. (C) Close up view of the catalytic core. 
UDP, glucose, and a manganese ion are bound on the surface of the core GT-A fold. 
The binding pocket is overlayed by a loop comprising residues 517-523. Some of the 
residues involved in coordinating UDP, Glucose, and Mn2+ are shown as sticks.  
 
 
Much less is known about the glucosyltransferase activity of TcdA. In one of the 
few studies comparing the glucosyltransferase activities of TcdA and TcdB, Chaves-
Olarte, et al. showed that TcdB was a much more active enzyme than TcdA (84). TcdB 
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was ~100 fold more potent at modifying RhoA, Rac1, and Cdc42. TcdB also had a 6.5 
fold higher rate of UDP-glucose hydrolysis in the absence of substrate. TcdA only 
outperformed TcdB in the modification of Rap2A, but even against this target, TcdA was 
a poor enzyme. When the toxins were microinjected into cells, TcdB had a 100 fold 
higher cytopathic potency than TcdA, correlating with the ~100 fold difference in 
glucosyltransferase activity. The authors concluded that this difference in 
glucosyltransferase activity was the major determinant in the 1000 fold difference in 
cytopathicity that had been reported previously. 
Many questions remain regarding the enzymatic activities of TcdA and TcdB 
such as why TcdA has a lower activity than TcdB and why it is able to modify additional 
substrates. The structural determinants of substrate binding and substrate specificity 
have not been worked out for any of the LCT/GTPase interactions. Nothing is known 
about the molecular mechanism of membrane localization for either TcdA or TcdB. 
Localization of the GTD to certain parts of the cell membrane and the potential presence 
of unknown cellular cofactors could significantly impact the actual array of in vivo targets. 
Moreover, the substrates of TcdA and TcdB have only been described from in vitro 
reactions. What substrates are actually being glucosylated in cells? In Chapter IV of this 
work, I describe the structure of the TcdA GTD and my efforts to begin addressing some 
of these questions. 
 
Research objectives 
 
 Crystal structures of a fragment of the TcdA RBD and the TcdB GTD have 
revealed a great deal about the molecular details of receptor binding and enzymatic 
inactivation of the target proteins. However, these two structures represent only a small 
part of the toxins. When we initiated this study, there was no structural information about 
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how the domains relate to each other or about the central 1300 amino acid region 
between the GTD and RBD for either toxin. This central region, which makes up about 
half of the toxin mass, contains the pore-forming and autoprotease domains responsible 
for the delivery of the GTD into the target cells. Furthermore, important differences have 
been noted in the glucosyltransferase and receptor-binding activities of TcdA and TcdB, 
highlighting the need for complementary structures of the TcdB RBD and the TcdA GTD.  
We have undertaken a structure-based study of TcdA and TcdB to address some 
of these gaps in our knowledge of the toxins’ functions. In Chapter III of this thesis, I 
describe my efforts to image the TcdA and TcdB holotoxins (HT) by negative stain 
electron microscopy and a 25 Å resolution structure of the TcdA HT obtained by random 
conical tilt. I have mapped the organization of the individual domains within the TcdA HT 
and visualized a pH dependent conformational change within the pore-forming domain.  
In addition, I have determined high-resolution structures of the TcdA cysteine 
protease and glucosyltransferase domains. Chapter II describes the 1.6 Å X-ray crystal 
structure of the TcdA CPD in complex with the activating molecule InsP6. 
Complementary functional studies demonstrate an intra-molecular mechanism of 
cleavage and highlight specific residues required for InsP6-induced TcdA processing. In 
Chapter IV, I present the structure of the TcdA GTD. This structure and accompanying 
biochemical data show that TcdA is not a defective enzyme but has comparable activity 
to TcdB when modifying Rho proteins. I confirm that TcdA does modify Rap proteins 
both in vitro and in cells whereas TcdB does not. Finally, I show that in the context of the 
holotoxin structure, the glucosyltransferase activity of TcdA and TcdB is inhibited. These 
structures provide a framework for understanding the molecular mechanism of cellular 
intoxication, not only for TcdA and TcdB, but for all members of the LCT family. 
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CHAPTER II 
 
 
STRUCTURE-FUNCTION ANALYSIS OF AUTOPROCESSING IN CLOSTRIDIUM 
DIFFCILE TOXIN A 
 
 
Introduction 
 
 Most AB toxins release their enzymatic A component into the cytosol of the target 
cell. The botulinum neurotoxin, for example, contains a zinc metalloprotease that is 
tethered to the rest of the toxin by a disulfide bond. Upon being delivered into the target 
cell, the disulfide bond is broken in the reducing environment of the cytosol, and the 
protease is liberated. In the case of anthrax toxin, the A components, edema factor and 
lethal factor, are expressed separately from the B component. After being delivered 
across the membrane, the unattached A components are free to enter the cytosol. 
Unlike other known AB toxins, the A component (GTD) of LCTs is released from the B 
subunits by an autoproteolytic cleavage event (134). The autoproteolytic release of the 
GTD is a recently described property of LCTs and represents a novel strategy employed 
by AB toxins to discharge their payload. 
Cleavage is triggered by host inositolphosphates such as InsP6 and the reducing 
environment of the cytosol (134). Autoproteolysis was initially attributed to an aspartate 
protease activity near the C-terminal RBD, the active aspartate being Asp1665. 
However, shortly after we initiated our studies on TcdA and TcdB, Egerer, et al. reported 
that cleavage was mediated by a CPD domain located within the N-terminal region of the 
B subunit (135). The putative autoprotease domain was identified based on homology 
with the CPD found in the MARTX toxins from gram-negative bacteria (136). Based on 
sequence homology between MARTX toxins and LCTs, the CPD was predicted to 
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comprise amino acids 543-769 of TcdB (135). Egerer, et al. identified three conserved 
residues within the CPD (Asp587, His653, and Cys698) that when mutated abrogate the 
autoprotease activity of TcdB. A subsequent study demonstrated that a protein 
containing TcdB residues 1-955 is sufficient for autoprocessing, showing that the CPD, 
not the reported aspartate protease activity, is responsible for InsP6-inducible cleavage. 
Autoprocessing in the MARTX toxin from Vibrio cholera (VcRTx) is also 
stimulated by InsP6 (137). A recent crystal structure of VcRTx CPD bound to InsP6 
suggests a novel mechanism of InsP6-induced allosteric activation (138). The CPDs of 
TcdA and VcRTx share only 19% sequence identity. To gain insight into the mechanistic 
commonalities between these entirely different toxins and to delineate the LCT-specific 
modes of InsP6-induced processing, we performed structural and functional analyses on 
the cysteine protease from TcdA.  
 
Methods 
 
Plasmid construction and point mutants 
The nucleotide sequence coding for amino acids (aa) 543-809 of TcdA (TcdA 
CPD) was amplified from C. difficile strain 10463 genomic DNA. The DNA was cloned 
into a modified pET27 vector such that the resulting protein contains an N-terminal His10 
tag followed by a 3C protease cleavage site. The sequence preceding the TcdA CPD 
sequence is MGSSHHHHHHHHHHGSSLEVLFQGPGS. Following 3C cleavage, only 
non-native residues GPGS remain. The extended construct, TcdA g-CPD, encodes aa 
510-809. This plasmid was constructed similarly except the last two residues of the 
leader sequence are VD rather than GS. Point mutants were generated by QuikChange 
site-directed mutagenesis. 
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Protein Expression and Purification 
Transformed E. coli BL21(DE3) cells were grown in terrific broth containing 50 
mg/L kanamycin. 10 mL of overnight culture was used to inoculate 1 L of media and the 
cultures were placed at 37°C and 230 rpm. When the cultures reached OD600 = 0.6, the 
temperature was changed to 16°C and expression was induced by the addition of 0.5 
mM IPTG. After 16 h the cells were harvested by centrifugation and resuspended in 100 
mM NaCl, 20 mM Tris, pH 8.0. Following French Press lysis, the lysates were 
centrifuged at 48,000 g for 20 min. Protein was purified from the supernatant by Ni-
affinity chromatography. For crystallization trials, the His10 tag was cleaved from TcdA 
CPD by 3C protease overnight at 4°C. The mixture was then run back over a Ni-
nitrilotriacetic acid agarose column to remove the cleaved His10-tag and the His-tagged 
3C protease. Cleaved TcdA CPD was further purified by gel filtration chromatography in 
50 mM NaCl, 20 mM Tris, pH 8.0. Selenomethionine substituted TcdA CPD was 
prepared using E. coli BL843(DE3) in minimal media containing 40 mg/L L-
selenomethionine following the same procedure, except 5 mM methionine and 1 mM 
DTT were added to the buffers to prevent oxidation of the selenium. TcdA g-CPD and 
mutants used for cleavage assays were expressed as above and purified by Ni-affinity 
and ion exchange chromatography. The His10-tag was not cleaved for these proteins. 
 
Crystallization 
TcdA CPD was concentrated to 60-80 mg/mL in 50 mM NaCl, 20 mM Tris, pH 
8.0. InsP6 (Sigma) was added to 10 mM. TcdA CPD was crystallized by the hanging-
drop method at 21°C with a 1:1 ratio of protein and mother liquor containing 100 mM 
Tris, pH 8.0-9.0, 25-30% PEG 8000, and 200 mM guanadinium chloride. Crystals were 
mounted on cryo loops and flash cooled in liquid nitrogen. No cryoprotectants were 
required. 
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Structure Determination and Refinement 
X-ray data were collected from single crystals on LS-CAT beamlines 21-ID-D and 
21-ID-G at the Advanced Photon Source (Argonne, IL). Diffraction data were indexed, 
integrated, and scaled using HKL2000 (155). Phases were determined from anomalous 
scattering data using autoSHARP (156). The model was built using Coot (157) and 
refined using Phenix (158) with riding hydrogens and seven TLS groups per chain (Table 
2-1). The final model contains 2 CPD molecules (consisting of residues 547-570 and 
575-801 for chain A and 548-570, 578-655, and 661-803 for chain B), 2 InsP6 
molecules, and 649 water molecules.  
 
InsP6  Induced Cleavage Assays 
TcdA g-CPD and g-CPD mutant proteins were exchanged into 60 mM NaCl, 250 
mM sucrose, 20 mM Tris, pH 7.5. 100 µL protein at 5 µM was mixed with 1 µL buffer or 
InsP6 stock solution and incubated at 37°C. After 2 h, the reaction was stopped by the 
addition of loading buffer and heating. For the time course reactions, 1 mL 5 µM protein 
was treated with 10 µL 500 µM InsP6. At the indicated time-points, 50 µL aliquots were 
removed; SDS loading buffer was added; and the samples were heated for 5 min. The 
samples were analyzed by SDS-PAGE with Coomassie staining.  
 
NMR spectroscopy 
  TcdA CPD was expressed and purified as described for crystallography, except 
that for 2D NMR, TcdA CPD was expressed in M9 minimal media with 15NH4Cl as the 
only nitrogen source. The protein was exchanged into a 50 mM NaCl, 50 mM potassium 
phosphate, pH 7.0 buffer by gel filtration chromatography and concentrated to 0.6 mM 
+/- 5 mM InsP6. NMR data were recorded at 25°C on a Bruker DRX600 spectrometer 
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with a 5 mm TXI-Z cryoprobe and processed with Topspin 2.0b (Bruker). 2D images 
were prepared with Sparky. 
 
Table 2-1. X-ray data collection and refinement statistics for the crystal structure 
of the TcdA CPD. 
 
Data Collection Native Selenium 
Wavelength, Å 0.9784 0.9784 
Resolution (outer shell)1, Å 50-1.6 (1.66-1.60) 50-1.8 (1.86-1.80) 
Rmerge2, % 4.3 (26.8) 5.5 (26.6) 
Mean I/σI  23.5 (2.4) 24.9 (6.7) 
Completeness, % 96.2 (81.9) 99.6 (96.5) 
Redundancy 4.8 (2.8) 7.6 (6.9) 
Unique observations 68,137 (5,753) 47,174 (4,525) 
Anomal. phasing power  1.226 
Refinement  
Rcryst/Rfree3 ,% 16.54/19.67 
No. protein atoms 4007 
No. ligand atoms 84 
No. solvent waters 649 
Bond length rmsd, Å 0.011 
Bond angle rmsd, ° 1.469 
Avg. protein B, Å2 39 
Ramachandran plot4, %  
  Most favored  417 (92.3%) 
  Allowed  33 (7.3%) 
  Generously allowed  1 (0.2%) 
  Disallowed 1 (0.2%) 
1 Outer resolution bin statistics are given in parentheses.  
2 Rmerge =  Shkl(Si|Ihkl,i - <Ihkl>))/Shkl,i<Ihkli>, where Ihkl,i, is the intensity of an individual measurement 
of the reflection with Miller indices h, k and l, and <Ihkl> is the mean intensity of that reflection.  
3 Rcryst = S||Fobs, hkl| - |Fcalc, hkl||/|Fobs, hkl|, where |Fobs, hkl| and |Fcalc, hkl| are the observed and 
calculated structure factor amplitudes. Rfree is equivalent to Rcryst but calculated with reflections 
(5%) omitted from the refinement process. 
4 Calculated with PROCHECK (159). 
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Results 
 
Defining the TcdA cysteine protease domain 
 TcdA and TcdB holotoxins undergo auto-proteolysis in the presence of InsP6 and 
DTT to release an N-terminal glucosyltransferase domain (residues 1-542 for TcdA) 
(133). In TcdB, the autoproteolytic activity and InsP6 binding have been mapped to 
fragments corresponding to residues 1-955 and residues 544-955, respectively (139). 
Sequence alignment with VcRTx suggests domain boundaries of 543-769 (TcdA) and 
543-767 (TcdB) (135). To define a structural domain required for TcdA auto-proteolysis, 
we designed a construct for the recombinant expression of TcdA 510-809. The 33 
residues from the glucosyltransferase domain C-terminus were included to provide a 
substrate for the enzyme and to permit visualization of cleavage by SDS-PAGE (Figure 
2-1A). Incubation of this 37 kDa protein, g-CPD, with InsP6 causes proteolysis resulting 
in two cleavage products of 30 kDa (CPD) and 7 kDa (g). When InsP6 and TcdA g-CPD 
were mixed in equal molar ratios, proteolysis occurred quickly with 50% of the protein 
cleaved in about 10 minutes (Figure 2-1B). A shorter construct corresponding to TcdA 
residues 510-769 did not undergo cleavage, even when InsP6 was added in excess 
(data not shown).  
 
Structure of the TcdA cysteine protease domain 
 TcdA amino acids 543-809, henceforth TcdA CPD, was crystallized in the 
presence of InsP6 and the structure was determined at 1.6 Å (Table 2-1, pdb 3HO6). 
The asymmetric unit contained two CPD molecules, which align with an rmsd of 0.236 Å 
based on the backbone α-carbon positions. For the remainder of this chapter we refer to 
chain A. The TcdA CPD is composed of a nine stranded β-sheet flanked by 5 α-helices 
(Figure 2-2). The closest structural homolog is that of the VcRTx CPD (pdb 3EEB, (138)) 
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which aligns with an rmsd of 2.9 Å over 187 residues (Figure 2-3), while the next closest 
homolog is caspase-7 (pdb 1SHJ, (160)), aligning with an rmsd of 4.8 Å over 135 
residues.  
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Figure 2-1. Defining the TcdA CPD. (A) TcdA is an AB toxin with four functional 
domains. The CPD is defined in this work as residues 543-809 based on the InsP6-
induced activity of g-CPD, residues 510-809. (B) Time course of g-CPD (5 µM) cleavage 
in the presence of 5 µM InsP6 shows 50% cleavage within 10 minutes.  
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Figure 2-2. Structure of the TcdA CPD bound to InsP6. TcdA CPD is shown as a 
ribbon diagram with InsP6 and the side chains of Cys700, His655, Asp589, and Cys597 
shown as sticks. The InsP6 binding site and catalytic site are separated by a three-
stranded β-flap (blue). The central β-sheet is shown in yellow. The N-terminus (red) 
wraps around the domain with the most N-terminal residues near the catalytic site. 
 
 
In both the VcRTx and TcdA CPD structures, InsP6 binds on one face of the β-
sheet and is separated from the proposed active site (Cys700, His655, and Asp589 in 
TcdA) by a three-stranded β-hairpin structure termed the β-flap (Figure 2-2, 2-4). The N-
terminus of the protein wraps around the exterior of the domain with the most N-terminal 
of the resolved residues (Gly547) near the proposed catalytic site (Figure 2-2). The TcdA 
CPD contains about fifty more residues than the VcRTx CPD, which leads to additional 
β-strands at the top and bottom of the β-sheet and two additional α-helices (Figure 2-3, 
2-4). The two cysteines of the TcdA CPD domain (Cys597 and Cys700) are more than 
20 Å apart, consistent with the observation that reductants are not needed for InsP6-
induced auto-processing of g-CPD (Figure 2-1). The fact that reducing agents enhance 
the auto-processing of holotoxin (135) suggests the presence of a disulfide involving at 
least one cysteine from another domain.  
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Figure 2-3. Overlayed comparison of the TcdA and VcRTx CPD structures. The 
TcdA (green) and VcRTx (blue) CPDs are shown as overlayed ribbon diagrams with 
InsP6 shown as sticks. Lysine residues 577, 766, 777, and 794 from TcdA CPD are 
shown as orange sticks. Secondary structure elements that are present in the TcdA CPD 
but not the VcRTx CPD are labeled. 
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Figure 2-4. Comparison of the TcdA and VcRTx CPD structures and sequences. 
(A-B) The structures of the TcdA (A) and VcRTx (B) CPDs are shown in the same 
orientation with the secondary structural elements annotated and color coded (α-helices 
in green; β-strands in blue). We have labeled the secondary structural elements to 
maintain consistency with the VcRTx CPD and caspase-7 literature. (C) The TcdA and 
VcRTx CPD sequences were aligned based on their structures (161) and displayed 
using ESPript (162). Strictly conserved residues are shown in white letters with a red 
background. Residues that are similar are boxed in red letters with white backgrounds. 
The secondary structural elements are marked above and below the sequences and the 
numbering corresponds to that of TcdA. 
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TcdA CPD active site 
 In cysteine proteases, the nucleophilicity of the active site cysteine is typically 
enhanced by hydrogen bonding to an adjacent histidine. Often, an additional negatively 
charged residue, such as aspartic acid, is present to stabilize the positive charge of the 
histidine. TcdA Cys700, His655, and Asp589 align to residues that have been implicated 
as catalytic residues in TcdB CPD (135,139) and VcRTx CPD (137). To address the role 
of these residues in autoproteolysis of TcdA, each was mutated within g-CPD and the 
proteins were tested for InsP6-inducible cleavage. Mutation of Cys700, His655, or 
Asp589 abrogates InsP6-inducible cleavage (Figure 2-5A). The adjacent Asp590 cannot 
substitute for Asp589, and mutation of Asp590 does not cause a defect in protease 
activity (Figure 2-5A). While these results are consistent with a catalytic triad, the 
structure indicates that while His655 and Asp589 are in hydrogen bonding contact, 
Cys700 is > 6 Å from His655 and >10 Å from Asp589 (Figure 2-5A). This arrangement, 
which we also observe in the CPD structure of VcRTx, suggests that the mechanism of 
catalysis in this class of self-cleaving proteases may be different from one in which a 
catalytic triad is in place. 
 
Intramolecular cleavage by CPD 
 To test whether InsP6-induced cleavage in TcdA is inter- or intramolecular, we 
mutated the conserved P1 residue from leucine to alanine (L542A) in g-CPD. This 
mutation prevented InsP6-inducible cleavage at the normal cleavage site (Figure 2-5C). 
When this mutant was mixed with the catalytic cysteine mutant, g-CPD C700S, no 
cleavage was observed. The g-CPD L542A was unable to cleave the normal cleavage 
site of g-CPD C700S suggesting that intermolecular cleavage does not occur for TcdA. 
In the crystal structure of TcdA CPD, residues 543-546 are unstructured. In TcdA CPD 
containing an intact cleavage site, the unstructured residues 543-546 likely extend into 
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the catalytic site. The structure of the TcdA CPD suggests that Leu542 may bind in a 
hydrophobic pocket located between the catalytic cysteine and the β-flap (Figure 2-
5B,D). This pocket is made up of the residues Ile591, Ala 595, Ile653, Leu698, Val746, 
Ile748, and Trp763 (shown in green in Figure 2-5), which are mostly conserved among 
LCTs (Figure 2-6).  
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Figure 2-5. Catalytic site of the TcdA CPD. (A) Wild-type, C700S, H655A, D589N, and 
D590N g-CPD at 5 µM were incubated with 100 µM InsP6 for 2 h at 37°C. In contrast to 
wild-type and D590N, the C700S, H655A, and D589N mutants were unable to undergo 
InsP6-inducible cleavage. (B) Ribbon diagram of the catalytic site of CPD (gray) with 
residue side chains of the catalytic site (orange) and hydrophobic pocket (green) shown 
as sticks. Other side chains within the active site are colored gray. (C) L542A g-CPD 
(cleavage site mutant) does not undergo cleavage upon addition of InsP6. When C700S 
and L542A g-CPD are mixed, no InsP6-dependent cleavage is observed. (D) Surface 
representation of the catalytic site reveals a likely substrate-binding pocket. The D589, 
H655, and C700 residues are colored orange and the hydrophobic residues are colored 
green. The orientation is identical to that in (B). 
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Figure 2-6. Conserved residues of the CPD. The TcdA CPD sequence 
(YP001087137) was aligned to sequences from four LCTs (TcdB (CAC19891), TcsL 
(CAA57959), TpeL (ACF49258), Tcnα (CAA88565)) and five diverse homologs found in 
gram-negative bacteria (VcRTx (ZP01975348), VsRTx (ZP00989505), Plu3217 
(NP930444), PmHI4320 (YP002151764), AhRTx (YP855898)) using ClustalW (163). 
There are 14 strictly conserved residues shown in white letters with a red background.  
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Binding of InsP6 
 The InsP6 molecule is highly charged, bearing six negatively charged phosphate 
groups, and accordingly, binds within a positively charged pocket of the TcdA CPD 
(Figure 2-7). Binding of InsP6 results in a significant stabilization of TcdA CPD as 
reflected by an increased resistance to digestion by chymotrypsin (Figure 2-8). Efforts to 
obtain crystals of the TcdA CPD in the absence of InsP6 were unsuccessful, so NMR 
spectroscopy was used to assess the nature of InsP6-induced structural changes. The 
1D 1H NMR spectrum of apo TcdA shows excellent dispersion of the signals indicative of 
a well-folded globular domain (Figure 2-9A, lower trace). Addition of InsP6 into the 
sample resulted in a substantial perturbation of the signals with an even greater 
dispersion (Figure 2-9A, upper trace). This is most evident in the very high field methyl 
region (-0.4 – 0.4 ppm) and the very low field amide region  (8.4-10.4 ppm, inset) of the 
spectrum. 2D 1H-15N NMR spectra of the CPD also reveal a larger number of shifted 
peaks in the presence InsP6 (Figure 2-9B). These data indicate that the TcdA CPD is 
folded in the absence of InsP6 and imply that InsP6 binding induces significant 
conformational reorganization and structural stability within TcdA CPD.  
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Figure 2-7. InsP6 binding pocket. (A) The TcdA CPD (left) and VcRTx CPD (right) 
surfaces colored by electrostatic potential (negatively charged surfaces are red; 
positively charged regions are blue, and neutral regions are shown in white) 
demonstrate that InsP6, shown as a stick model, binds in positively charged pockets. 
The protein molecules were aligned and are shown in identical views but the orientation 
of the InsP6 molecules and the position of the axial phosphate groups (denoted with an 
asterisk) differs. (B) InsP6 and the side chains of residues that directly interact with 
InsP6 are shown as sticks. The orientation is identical to that in (A). The displayed 
electron density is a 2Fo-Fc map contoured at 5σ in which InsP6 was omitted from the 
phase calculations. (C) WT, K577N, K602N, K754N, and K794N g-CPD at 5µM were 
tested for autoproteolysis over a range of InsP6 concentrations. Each mutant required 
10-1000 fold more InsP6 in order to undergo autoproteolysis at levels comparable to 
wild-type.  
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Figure 2-8. Effect of InsP6 on the structural stability to the TcdA CPD. TcdA CPD 
(at 1 mg/mL in 50 mM NaCl, 20 mM Tris, pH8.0) was incubated with chymotrypsin for 1 
hour at 25°C. The presence of 1 mM InsP6 provides protection from proteolysis. Similar 
results were obtained with trypsin (data not shown).  
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Figure 2-9. InsP6-induced structural changes. (A) 1D 1H-NMR spectra of the TcdA 
CPD in the presence (upper trace) and absence (lower trace) of InsP6 show clear 
dispersion of peaks indicative of folded proteins. The inset shows major changes in the 
peaks suggesting that significant structural changes are induced by InsP6 binding. (B) 
An 15N-1H spectrum in the absence of InsP6 shows a clear dispersion of peaks indicative 
of a folded protein. More peaks are visible in the presence of InsP6. An overlay suggests 
that significant structural changes are induced by InsP6 binding. 
 
 
  
 48         
Insights into the effects of InsP6 binding on TcdA CPD are provided by the high 
resolution structure of the complex. The TcdA CPD has nine residues that make direct 
contacts with the InsP6 (Figure 2-7B). These include one arginine (Arg753), one tyrosine 
(Tyr579), and seven lysines (Lys577, 602, 649, 754, 766, 777, and 794). Thus, binding 
of InsP6 involves residues spanning the entire domain, consistent with the significant 
reorganization of the structure upon binding. Lys794, which is conserved among all 
LCTs except TpeL of C. perfringens (Figure 2-6), coordinates the axial phosphate group 
of the InsP6. This residue is located on the C-terminal β-strand, which is entirely absent 
from the VcRTx CPD. Thus, the position of the axial phosphate group and the orientation 
of the InsP6 in the VcRTx CPD structure are markedly different from that in TcdA CPD 
(Figure 2-7). 
 In VcRTx CPD, Lys602, 754, 766, 777, and Arg753 are conserved and important 
for binding InsP6 and proteolysis (Figure 2-4) (138). To test the importance of both 
conserved and unique InsP6-binding interactions in TcdA autoproteolysis, lysine 
residues 577, 602, 754, and 794 were mutated to asparagine in the g-CPD protein 
background and tested for InsP6 inducible cleavage (Figure 2-7C). The mutant proteins 
required 10-1,000 times higher concentrations of InsP6 to achieve an equivalent amount 
of cleavage as wild type g-CPD, confirming the significance of each of these InsP6 
ligands. 
 
The β-flap 
 In the structural analysis of VcRTx, Lupardus et al. propose the β-flap as a link 
between InsP6 binding and the catalytic site (138). In TcdA, the β-flap contains a 
network of amino acid side chains that may be involved in transmitting InsP6-induced 
structural changes to the active site (Figure 2-10). The active site side of the β-flap 
includes Val746, Ile748 and Trp763, residues that line the hydrophobic pocket thought to 
  
 49         
be involved in binding the P1 residue of the substrate (Leu542) (Figure 2-5B,D). On the 
InsP6 side of the β-flap, the conserved Arg753-Lys754 pair and Lys766 directly 
coordinate the InsP6 (Figure 2-7B, 2-10). Lys766 is located at the beginning of α4, a 
structural element not found in the structure of VcRTx CPD. In addition to interacting 
with InsP6, the α4 helix stabilizes the β-flap with an electrostatic interaction between 
Glu768 and Lys762 (Figure 2-10). Arg747 also stabilizes the β-flap structure. This is 
through an electrostatic interaction with Glu755 and a π-cation interaction with Trp763 
(Figure 2-10). While Trp763 is strictly conserved in the broad family of CPD sequences, 
the Arg747 and Glu757 residues are only conserved within the LCTs (Figure 2-6). In 
VcRTx, and other homologs from gram-negative bacteria, the residue corresponding to 
Arg747 is an alanine. Efforts to analyze a TcdA CPD R747A mutant failed due to protein 
instability, implying a role for Arg747 in the absence of InsP6. Thus, in TcdA (and likely 
all LCTs) the β-flap is an important structural element both in separating the InsP6-
binding and substrate-binding sites and in contributing to the global stability of the fold. 
 
Discussion 
 
 TcdA and VcRTx represent two classes of large toxins that target the eukaryotic 
cytoskeleton through very different mechanisms. The proteins contain a single region of 
homology, the CPD, which is involved in proteolytic processing of the toxins. 
Comparison of the atomic structures from these highly divergent domains provides an 
opportunity to gain insight into the selective pressures needed for function in both 
systems.  
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Figure 2-10. TcdA CPD β-flap. A close up of the β-flap (blue) reveals a network of 
interactions that link InsP6 (red) to the catalytic site (Cys700, His655 and Asp589). 
 
 
 The CPD from TcdA is larger than that of VcRTx and contains a C-terminal 
extension that was not readily apparent through sequence analysis. The observation that 
Lys777 and Lys794 are involved in coordination of InsP6 provides ready explanation for 
the lack of activity in the 510-769 construct we made based on sequence alignment with 
VcRTx. The altered conformation of InsP6 within the active site reflects the contributions 
from this C-terminal extension as well as other structural differences in the TcdA and 
VcRTx InsP6 binding sites. Lys766 is presented by the α4 helix, not present in VcRTx, 
and the loop containing Lys577 is positioned very differently in the two molecules (Figure 
2-3). The capacity to evolve differences in how InsP6 (and related molecules) are bound 
has been noted in the family of RNA editing enzymes (164) and could be relevant in a 
newly identified and largely uncharacterized family of CPD homologs from bacteria and 
eukaryotes (165). 
 The VcRTx and TcdA CPD structures were obtained in the presence of InsP6. 
The dispersion of peaks observed in the apo- and InsP6-bound proteins by NMR 
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suggest that both proteins are folded but that InsP6 binding confers stability and induces 
significant structural change (2-9). This is not unexpected given the energetically 
unfavorable accumulation of positive charges that one would predict in the absence of 
InsP6 (Figure 2-7). We propose that the energetic gains of complementing these positive 
charges with InsP6 allow the molecule to overcome the energetic barrier needed to 
access its active conformation. An example of such an allosteric transition in a single 
domain protein has been documented in the phosphorylation of the NtrC response 
regulator (166). Recent work by Shen et al. has demonstrated that the TcdB CPD exists 
in a dynamic equilibrium between active and inactive states (167). InsP6 binding shifts 
the equilibrium markedly toward the active conformation. Shen, et al. showed by 
mutational analysis that the β-flap does, in fact, play an important role in the allosteric 
activation mechanism through coupling the InsP6-binding and catalytic sites. 
 A trio of aspartate, histidine, and cysteine residues has been shown to be 
essential in the auto-proteolytic processing of VcRTx (137), TcdB (135), and TcdA (this 
work). The structures of the TcdA and VcRTx CPDs, however, indicate that these 
residues do not adopt a conventional catalytic triad arrangement. Instead, the cysteine 
and histidine residues are separated by a large cavity which is likely to serve as the 
substrate-binding pocket (Figure 2-5B,D). In TcdA, this pocket is ~11Å long, ~7Å wide, 
~7Å deep and bounded by α1, the β-flap, and the loop containing His655. One end of 
the cavity is hydrophobic and believed to represent a binding site for the P1 leucine 
residue of the substrate. While His655 is on a flexible loop and could re-orient in the 
presence of substrate, the structural changes needed to account for the observed 
importance of Asp589 would be substantial and require rearrangement of α1 and 
occlusion of the substrate binding cavity (Figure 2-5B).  
An inactive VcRTx CPD, with the catalytic cysteine mutated to a serine, has 
recently been crystallized with the P1 leucine bound in the active site (pdb 3FZY (168)). 
  
 52         
Even in this structure with the substrate bound, the mutated residue, C6538S, remains 
separated from the hydrogen bonded His-Asp pair. The substrate chain lies between 
them. Structures of the TcdB CPD have also been determined recently, and the active 
site residues are likewise separated (pdb 3PEE and 3PA8 (167,169)).  
Thus, despite biochemical evidence consistent with a catalytic triad, the TcdA 
and VcRTx CPD crystal structures indicate that the histidine and aspartate residues are 
not positioned to increase the nucleophilicity of the cysteine. Rather, His655 may be 
acting as an oxyanion hole with Asp589 important in its capacity to orient His655. TcdA 
and VcRTx CPDs may employ a primitive mechanism of proteolysis wherein the need to 
“activate” the nucleophile is obviated by the intramolecular and/or single turnover nature 
of the reaction. Mutant serine proteases in which the histidine and aspartate have been 
removed from the catalytic triad still catalyze reactions with ~10,000 fold rate 
enhancements (170), explained largely by their ability to constrain substrate and 
stabilize the developing oxyanion (171).  
 In summary, we have shown that the CPD of TcdA is able to use InsP6 to 
activate an intra-molecular auto-proteolytic processing event. The structural analysis 
reveals striking similarities in the mechanisms of TcdA and VcRTx InsP6-inducible 
cleavage but also shows differences in the conformation of InsP6 and the organization of 
the β-flap. These observations should aid the elucidation of unique and conserved 
molecular features required for virulence in TcdA, the LCTs and the larger family of 
CPDs from MARTX toxins.  
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 CHAPTER III 
 
STRUCTURAL ORGANIZATION OF THE FUNCTIONAL DOMAINS OF 
CLOSTRIDIUM DIFFICILE TOXINS A AND B 
 
 
Introduction 
  
 The action of LCTs on mammalian target cells depends on a multi-step 
mechanism of receptor-mediated endocytosis, membrane translocation, autoproteolytic 
processing, and mono-glucosylation. Many of these functional activities have been 
ascribed to discrete regions within the primary sequence suggesting that the toxins will 
adopt multi-modular three-dimensional structures (Figure 1-4). LCTs are important 
virulence factors, but structural data on these proteins have thus far been limited to 
crystal structures of a few isolated domains. With the exception of an analysis of TcdB 
by small angle X-ray scattering (SAXS) (172), the holotoxin structures of these 
molecules have not been characterized.  
We have imaged TcdA and TcdB using electron microscopy (EM) and shown 
that they share many similar structural features. We have determined a three-
dimensional (3D) structure of the TcdA holotoxin at neutral pH by negative stain EM and 
experimentally mapped three of the four functional domains to discrete regions within the 
density. These data allow us to evaluate structural models of the TcdA receptor-binding 
domain (115,124), the TcdA autoprotease domain (173), and the TcdB 
glucosyltransferase domain (150) within the architecture of the holotoxin. In addition to 
the analysis at neutral pH, we present images of TcdA after autoprocessing and after 
exposure to acidic pH. A 3D structure at low pH suggests that the conformational 
changes required for translocation of the glucosyltransferase domain into the host 
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cytosol will be significant. Since members of the LCT family are similar in many aspects 
of sequence and function, these structures of TcdA at neutral and acidic pH provide a 
framework for understanding the molecular mechanism of cellular intoxication for all 
members of the LCT family. 
 
Methods 
 
Cloning 
DNA corresponding to the TcdA receptor-binding domain (aa 1832-2710), TcdA 
protease domain (aa 543-795), TcdA delivery domain (aa 799-1859), and TcdA D1-
delivery sub-domains (aa 799-1460 and 771-1460) was amplified from C. difficile strain 
10643 genomic DNA. The TcdA domains were cloned into a modified pET27 vector such 
that the resulting proteins contains an N-terminal His10 tag separated from the protein by 
a 3C protease cleavage site. After 3C cleavage, only non-native residues GPGS remain. 
DNA corresponding to the TcdB holotoxin was cloned into a pHis1622 (MoBiTec, 
BMEG20) vector using the restriction sites BsrGI and KpnI. The nucleotide sequence 
corresponding to the TcdA GTD (aa 1-542) was cloned into pHis1622 using the BsrGI 
and SphI restriction sites. 
 
Protein expression and purification 
Native TcdA was obtained from the supernatant of C. difficile strain 10643 grown 
in dialysis sac culture, as described previously (3). TcdA was purified from the 
supernatant by multiple rounds of anion-exchange chromatography, followed by gel-
filtration chromatography in 150 mM NaCl, 20 mM Tris, pH 8.0. The identity of TcdA was 
verified by mass spectrometry. TcdB was expressed in Bacillus megaterium as 
described previously (174) except cells were harvested ~4 h post induction. The TcdA-
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GTD was expressed the same way. All of the other recombinant TcdA domains were 
expressed from E. coli as reported previously for the autoprotease domain (173), except 
BL21(DE3)-CodonPlus  cells (Stratagene) were used. Accordingly, 35 mg 
chloramphenicol was added for every liter of media. At the final step in purification, 
proteins were exchanged into 50 mM NaCl, 50 mM potassium phosphate, pH 7.0 by gel 
filtration chromatography.  
 
Autoproteolysis of TcdA 
100 µg of purified TcdA in 150 mM NaCl, 20 mM Tris, pH 8.0 was mixed with 100 
mM InsP6 and 100 mM DTT and incubated at 37 ºC for 3 hours. Some of the protein 
precipitated during this process. Protein that remained soluble was run on a S200 gel-
filtration column in 150 mM NaCl, 20 mM Tris, pH 8.0. 
 
Specimen preparation and electron microscopy 
Uranyl formate (0.7% mass/volume) was used for conventional negative staining 
as described (175). The low-pH TcdA delivery domain and TcdA holotoxin grids were 
prepared as above, except the grid was washed with 50 mM sodium citrate, pH 4.5 
instead of water. 
 Images of TcdA holotoxin at neutral and low-pH were recorded using a Tecnai 
T12 electron microscope (FEI) equipped with a LaB6 filament and operated at an 
acceleration voltage of 120 kV. Images were taken under low-dose conditions at a 
magnification of 67,000X using a defocus value of –1.5 mm. Images were recorded on 
DITABIS digital imaging plates (Pforzheim, Germany). The plates were scanned on a 
DITABIS micron scanner (Pforzheim, Germany), converted to mixed raster content (mrc) 
format, and binned by a factor of 2 yielding final images with 4.48 Å/pixel. Images of 
cleaved TcdA were collected under similar conditions except images were recorded 
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using a 2048 x 2048 pixel Gatan CCD camera. Cleaved TcdA images were also 
converted to mrc format, and binned by a factor of 2 resulting in final images with 3.0 
Å/pixel.  
 Images of TcdB and the TcdA delivery domain were collected on a Tecnai F20 
electron microscope equipped with a field emission electron source and operated at an 
acceleration voltage of 120 kV under low-dose conditions at a magnification of 100,000X 
and a defocus value of -1.5 mm. Images were collected using a Gatan 4Kx4K CCD 
camera. CCD images were converted to mrc format and binned by a factor of 4 resulting 
in final images with 4.26 Ǻ/pixel. 
 Particle images of cleaved TcdA, TcdA delivery domain, and TcdB were selected 
with Boxer (176) and windowed with a 192 pixel (3.0 Å/pixel), 64 pixel (4.26 Å/pixel), and 
120 pixel (4.26 Å/pixel) side lengths, respectively. Image analysis was carried out with 
SPIDER and the associated display program WEB (177). 
 For antibody labeling, the proteins were mixed in approximately 1:2 mass ratios 
and incubated at room temperature for 3 h before grid preparation. Particle images of 
TcdA bound to 15A4 were selected with Boxer (176) and windowed with a 136 pixel side 
length.  
 
Random conical tilt reconstruction of negatively stained TcdA 
Micrograph tilt pairs of TcdA at neutral and low pH were recorded at 60˚ and 0˚. 
Particle pairs (7,396 at neutral pH and 8,319 pairs at low pH) were selected interactively 
from both the images of the untilted and 60˚ tilted sample using WEB, and windowed 
into 128 x 128 pixel images (4.48 Å/pixel). The untilted images were rotationally and 
translationally aligned and subjected to 10 cycles of multi-reference alignment and K-
means classification. Particles of neutral pH TcdA were grouped into 12 classes  (Figure 
3-1A). From the class averages, three representative projections were chosen and used 
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as references for another cycle of multi-reference alignment (Figure 3-1A, marked with a 
‘*’). TcdA particles at low pH were aligned to four references chosen from a previous 
alignment of ~4,000 images of TcdA at a low pH (Figure 3-3A, marked with a ‘*’).  
 The larger of the resulting classes for both the neutral pH and low pH TcdA 
particles (4,956 and 2,503 particles, respectively) (Figure 3-1B and 3-3B, marked with a 
‘*’) were used to calculate an initial 3D reconstruction by back-projection using the in-
plane rotation angles determined by rotational alignment and the pre-selected tilt angle 
of 60˚ implemented in the processing package SPIDER (177). The density map was 
improved by back-projection and angular refinement in SPIDER. 10% of the particles 
selected from the images of the untilted specimens in either the neutral or low pH class 
were included in the data set (500 and 250 particle images, respectively) and angular 
refinement was repeated. The Fourier shell correlation (FSC) curve corresponds to 
normalized cross-correlation coefficients of Fourier shells from even and odd particles 
within the dataset. Using a FSC = 0.5 criteria (Figure 3-1C and 3-3C), neutral and low 
pH structures were filtered to 25 Å and 30 Å resolutions, respectively. The 3D structure 
of the neutral pH TcdA structure was also filtered using the IMAGIC-V software package 
(178) using the THREED-SMOOTH command to diminish ‘salt and pepper’ noise from 
the map by removing single voxels that were unconnected to the main volume of the 3D 
density. The contouring threshold was chosen so that the volume of the each TcdA 
structure was continuous. The estimated molecular weight of each structure was then 
calculated in IMAGIC-V (178)  using this value and a protein density of 0.8 Da/Å3. The 
surface rendering of the structure was performed with the program Chimera (179). 
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Figure 3-1. EM analysis of TcdA. (A) Average of 7,396 TcdA particles classified into 12 
class averages. Boxes marked with “*” indicate averages used as references for (B). (B) 
Multi-reference alignment of 7,396 particles into 3 classes. The class indicated with “*” 
was used for the reconstruction. The numbers in each square indicate the number of 
particles in each class average. Each box has a side length of 57.3 nm. (C) FSC curve 
for neutral pH structure of TcdA.  
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Figure 3-2. EM analysis of TcdB. (A) A sample of single particle images that resemble 
TcdA. (B) Images of single particles that appear to be in a more ‘open’ conformation. (C) 
Averages of 2,133 TcdB particles grouped into 10 class averages. Boxes marked with “*” 
indicate averages used as references for (D). (D) Multi-reference alignment of 2,133 
particles into 4 classes. The numbers in each square indicate the number of particles in 
each class average. Each box has a side length of 51.1 nm. 
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Figure 3-3. EM analysis of low pH TcdA. TcdA was adsorbed to the grid, washed with 
50 mM sodium citrate, pH 4.5, stained with uranyl formate and visualized by EM. (A) 
Alignment of 4014 low-pH TcdA particles into 10 groups. The numbers indicate the 
number of particle averaged for each image. Boxes marked with “*” indicate classes 
used as references for (B). (B) Reference alignment of low-pH TcdA particles into 4 
classes. The classes indicated with “*” were used as references for 3D structure 
determination. The side length of each box is 57.3 nm. (C) FSC curve for low-pH 
structure of TcdA. 
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Generation of monoclonal antibodies 
 Four BALB/c mice were immunized with a fragment of the TcdA delivery domain 
corresponding to residues 771-1460. For primary injections, 50 µg of purified antigen 
were emulsified in 50% PBS, 50% Freund’s complete adjuvant and injected 
subcutaneously into the nape of the neck (50%) and intramuscularly to the gluteal 
muscles (50%). In subsequent booster injections, Freund’s incomplete adjuvant was 
substituted for Freund’s complete adjuvant. Four days after the final immunization, 
spleen cells were harvested and fused by standard methods with SP2/0 myeloma cells. 
Antibodies from the resulting hybridomas were screened by ELISA for interaction with 
the delivery domain (799-1460) and holotoxin, but not the glucosyltransferase, 
autoprotease, or receptor binding domains. Clones producing antibodies with the desired 
properties were subcloned to ensure monoclonality and cryopreserved. Monoclonal 
antibodies were purified from the supernatant of the selected clone by affinity 
chromatography on Protein-G sepharose (GE Life Sciences).  
 
ELISA for screening monoclonal antibodies 
 Either recombinant protein or native holotoxin at 5 µg/mL was coated onto 96-well 
ELISA plates at 4 ºC overnight. The wells were washed with PBST (PBS with 0.1% 
Tween) at least three times after this and every subsequent step. The wells were 
blocked with 1% BSA in PBST for 1 h at room temperature. The antibody 15A4 was 
diluted to 0.3 µg/mL in PBST and added to the plates for 1 h at room temperature. HRP-
conjugated goat anti-mouse-IgG antibody (Jackson) was added to the plates in PBST 
and incubated 1 hour. The ELISAs were developed by the addition of ABTS substrate 
solution (1mM ABTS (2,2’ azino-di-(3-ethylbenzthiozoline sulfonic acid)) (Sigma) in 70 
mM citrate-phosphate buffer, pH 4.2 w/ 0.03% H2O2) for 30 minutes, and absorbance 
was measured at 410 nm.  
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TcdA glucosyltransferase domain solubility assay  
Purified glucosyltransferase domain was exchanged into 150 mM NaCl, 10 mM 
Tris, pH 8 by gel filtration chromatography and concentrated to ~0.38 mg/mL. 18 µL 
protein was mixed with 2 µL 1 M sodium citrate at the indicated pH. After a 30 min. 
incubation at room temperature, the samples were centrifuged at 14000 g. The 
absorbance of the supernatant was measured at 280 nM.  
 
Results 
 
Visualization of TcdA and TcdB by negative stain electron microscopy 
 TcdA was purified from C. difficile culture supernatant (Figure 3-4B) and shown 
to be active in a cell-rounding assay. Toxin was adsorbed to carbon-coated glow-
discharged grids, and stained with uranyl formate. Negative stain electron microscopy 
(EM) revealed homogeneous particles with a non-symmetric shape and an elongated 
‘tail’ (Figure 3-4C). Image pairs of grids containing negatively stained TcdA were 
recorded at tilt angles of 60˚ and 0˚. A total of 7,396 particles were selected and images 
of the untilted specimens were classified into 12 class averages. These class averages 
revealed that while essentially all TcdA particles adsorbed to the carbon grid in the same 
orientation, there was some variation in the ability to resolve the elongated ‘tail’ (Figure 
3-1A). From the 12 classes we selected one that represented a well-resolved TcdA 
particle, one that represented a TcdA particle with poorly resolved ‘tail’ and one poorly 
resolved image (Figure 3-1A, marked with a ‘*’) and used them as references for another 
cycle of multi-reference alignment (Figure 3-1B). The largest of the three resulting 
classes (4,956 particles, Figure 3-4D and Figure 3-1B, marked with a ‘*’) showed a TcdA 
particle with many clear structural features (Figure 3-4D). The TcdB holotoxin was also 
purified and visualized by negative stain EM (Figure 3-4E). While a more heterogeneous 
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field of particles was seen than with TcdA (compare Figure 3-4C and F), the 
classification of 2,133 particles into 10 class averages revealed a number of classes that 
had similar structural features as observed in the TcdA alignment (Figure 3-2C). To 
improve the alignment we selected four classes as references for a round of multi-
reference alignment (Figure 3-1D, marked with a ‘*’). The largest of the four resulting 
classes (915 particles, Figure 3-4G and Figure 3-2D) showed a TcdB molecule with a 
well-resolved globular ‘head’ domain connected to two extended tails, structural features 
that are very similar to that of TcdA (Figure 3-4D). Although TcdA and TcdB are clearly 
structurally similar, the TcdA sample was more homogenous and a better candidate for 
structural characterization. For this reason further 3D analysis was done using TcdA. 
A 3D reconstruction of TcdA was generated using the random conical tilt 
approach (180) and is presented in Figure 3-5. The FSC curve calculated from our final 
density map suggests a resolution of ~25 Å based on the FSC = 0.5 criterion (Figure 3-
1C) (181). The face view of the 3D density map shows structural features very similar to 
those seen in the projection average (compare first panel in Figure 3-5 with Figure 3-4D) 
suggesting that the 3D reconstruction was successful. The 3D density map of TcdA 
adopts an elongated, asymmetric structure that is ~310 Å x ~150 Å x 90 Å in dimension. 
The structure contains three prominent features: a ‘head’ domain, a long kinked ‘tail’, 
and short inner ‘tail’. The head, ~ 90 Å x 90 Å x 60 Å in size, appears to contain two 
globular ‘pincher-like’ domains that are connected by a small density at the top of the 
head, thus creating a small channel that is ~20 Å wide and 90 Å deep. Emanating from 
the head domain are two tails. A long kinked tail extends from the bottom of the larger of 
the two ‘pincher’ domains and stretches ~ 270 Å in an undulating curve. A second tail 
domain connects from the smaller of the two ‘pincher’ domains, extending ~100 Å before 
making contact with the longer kinked tail domain.  
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Figure 3-4. Purification and characterization of TcdA and TcdB. (A) The proposed 
domain organization for TcdA and TcdB is shown. The numbers are for amino acids that 
mark domain boundaries. (B) SDS-PAGE of purified TcdA, visualized by Coomassie 
staining. (C) A typical electron micrograph showing TcdA particles in negative stain. A 
few of the particles are circled in black. Scale bar, 500 Å (D) A representative class 
average of TcdA particles (4,956) selected from images of untilted specimens in 
negative stain. Side length of panel is 57.3 nm. (E) SDS-PAGE of TcdB, visualized by 
Coomassie staining. (F) Electron micrograph of TcdB in negative stain with a few 
particles circled in black. Scale bar, 500 Å (G) Class average of 915 TcdB particles in 
negative stain. Side length of panel is 51.1 nm. 
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Figure 3-5. Random conical tilt reconstruction of TcdA in negative stain. 3D 
reconstruction of TcdA filtered to 25 Å. The structure is rotated about the vertical axis in 
60˚ steps or about the horizontal axis by 60˚ or 300˚ steps (in reference to the top left 
structure) as indicated by arrows. TcdA has an elongated shape with three distinct 
domains: a head domain, a long kinked tail, and a shorter straight tail. Scale bar is 5 nm. 
 
 
Identification of TcdA domains 
 To gain insight into how the functional domains of TcdA are organized in the 3D 
structure we performed direct domain visualization and domain subtraction experiments. 
The C-terminal domain of TcdA is composed of 39 sequence repeats and is responsible 
for binding cell surface carbohydrates (115). Crystal structures of two fragments from the 
C-terminus of TcdA revealed a β-solenoid fold, suggesting that the entire TcdA C-
terminal binding domain would adopt an elongated serpentine structure (115,124) 
(Figure 3-6A). Several features of this predicted model are seen in the long tail observed 
by EM (Figure 3-6A,B). To confirm that the long tail is indeed the binding domain, we 
expressed the TcdA binding domain (amino acids 1832-2710) in E. coli, purified it, and 
subjected it to negative stain EM (Figure 3-6C,D). The kinks, corresponding to the seven 
long repeats, and the approximate lengths of the straight sections observed by EM are 
consistent with the model derived by crystallography (115) (Figure 3-6). Thus, the long 
kinked tail domain found in our structure represents the C-terminal binding domain of 
TcdA. 
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Figure 3-6. Characterization and localization of the TcdA C-terminal binding 
domain. (A) The predicted model of the TcdA binding domain (115). (B) Average of 
4,956 TcdA particles (from Figure 3-4D). (C) Image of a single negative stained particle 
of the TcdA binding domain. (D) A typical electron micrograph area of the recombinantly 
expressed C-terminal domain of TcdA (aa 1832-2710). A few of the particles are circled 
in black. Scale bar, 500 Å. 
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Figure 3-7. Visualization of the TcdA delivery domain by negative stain EM. (A) A 
typical electron micrograph showing particles of the TcdA delivery domain. The particles 
have a globular shape resembling the ‘head’ of TcdA. Scale bar, 500 Å. (B-C) Two class 
averages of the TcdA delivery domain. Classes contain 139 and 314 particles 
respectively. Side length of panel is 27.2 nm (D) Class average of the head of TcdA. 
Side length of panel is 27.2 nm (E) TcdA delivery domain was applied to an EM grid, 
washed with sodium citrate at pH 4.5, and visualized by negative stain EM. Scale bar, 
500 Å. (F) Class average (405 particles) of the TcdA delivery domain following exposure 
to a low pH buffer. Side length of panel is 27.2 nm. 
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 To identify the location of the central TcdA delivery domain, we imaged a 
recombinantly expressed protein corresponding to residues 799-1859. The images 
suggest that the protein is capable of binding the grid in a variety of orientations (Figure 
3-7A), but classification of 1,523 particles into 5 class averages resulted in two classes 
of 139 and 314 particles (Figure 3-7B,C) that recapitulate the size, shape and pincher-
like features of the holotoxin head domain (Figure 3-7D). In an alternative approach, we 
labeled the toxin with a monoclonal antibody specific for the delivery domain (Figure 3-
8). The antibody bound at the top of the head to the larger of the two lobes providing 
further evidence that the head corresponds to the delivery domain. 
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Figure 3-8. Labeling TcdA with a monoclonal antibody against the delivery 
domain. (A) The monoclonal antibody 15A4 was tested by ELISA for recognition of 
native holotoxin and the TcdA glucosyltransferase (aa 1-543), autoprotease (aa 543-
795), delivery (aa 799-1460), and binding (aa 1832-2710) domains. Binding was 
detected using an HRP-conjugated secondary antibody. (B) TcdA was incubated with 
15A4 and visualized by negative stain EM. A gallery of labeled TcdA particles is 
depicted. Below each image is a schematic representation of how the antibody (red) is 
bound to TcdA (white). Side lengths of panels are 60.9 nm. (C) Two-dimensional view of 
15A4 antibody position (marked with ‘*’) on the 3D model of TcdA. Scale bar, 5 nm. 
 
 
The proposed function of this domain is to change structure in response to the 
low pH of the endosome and form a pore. To test whether such a structural change 
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would be visible by EM, we applied the protein to a grid and then washed the grid with a 
buffer at a pH of 4.5 before staining with uranyl formate (Figure 3-7E). The most 
populated class average from this analysis (Figure 3-7F) suggests that this domain is 
capable of changing into an extended conformation at low pH. 
 With the long tail identified as the receptor-binding domain, and the head 
identified as the delivery domain, we hypothesized that the small tail most likely 
represents the N-terminal glucosyltransferase domain. To test this, we induced 
autoproteolytic removal of the TcdA glucosyltransferase domain by incubating holotoxin 
with InsP6 and DTT (Figure 3-9A). The glucosyltransferase domain was removed by gel-
filtration chromatography and the larger fragment was analyzed by negative stain EM 
(Figure 3-9). Upon examining the images of cleaved TcdA (Figure 3-9B,C), it is clear that 
while the long tail and globular domains are still visible, the shorter tail is missing. Thus, 
the shorter tail domain seen in the 3D TcdA structure is the glucosyltransferase domain.  
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Figure 3-9. Localization of the TcdA N-terminal glucosyltransferase domain by 
autoproteolysis. Cleavage of TcdA was induced by the addition of InsP6 and DTT. (A) 
Coomassie stained SDS-PAGE of native TcdA and the larger fragment of TcdA following 
autoproteolytic cleavage and purification by size exclusion chromatography. (B-C) The 
large fragment containing residues 543-2710 was isolated, applied to a grid, stained with 
uranyl formate, and visualized by negative stain EM. (B) Representative image of 
cleaved TcdA particles in negative stain. Scale bar, 500 Å. (C) A gallery of TcdA cleaved 
particles. Although the head and long kinked tail domain are visible, the short tail region 
is missing. The side-length of each panel is 57.3 nm. 
  
 69         
45˚ 45˚
90˚
A
B
 
Figure 3-10. Placement of the functional domains of TcdA within EM map. (A,B) 
The 3D reconstruction of TcdA filtered to 25 Å is shown as mesh surface. Structures of 
the TcdB glucosyltransferase domain (red), the TcdA autoprotease domain (blue), and a 
model of the TcdA binding domain (green) were manually placed into the density. Panel 
B shows two views of the toxin enlarged to show the placement of the 
glucosyltransferase and protease domains. 
 
 
 A model of the binding domain of TcdA was placed into the 3D EM map (Figure 
3-10). The N-terminus of the domain connects to the back of the head near the larger of 
the pincher domains, whereas the C-terminus extends away from the rest of the toxin. 
As is common for negative stained specimens, the binding domain was somewhat 
flattened in the EM map compared to the model. The distortion was fairly minor, 
however, and most of the model clearly and unambiguously fit into the EM map. The 
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crystal structure of the glucosyltransferase domain of TcdB was placed into the small tail 
in the EM map with the N-terminus distal from the head domain (Figure 3-10). The 
domain is 90 Å long, consistent with the ~100 Å length of the short tail, and is about 25 Å 
wide at the extreme N-terminus. The C-terminal side of the domain is considerable 
larger with a diameter of about 65 Å. The small tail in the EM map has a narrow distal 
end and a larger, wider region near the head that is consistent with the shape of the 
TcdB glucosyltransferase domain. We did not determine the location of the autoprotease 
domain experimentally. However, there are only four amino acids between the 
glucosyltransferase and autoprotease domains that are not present in either crystal 
structure. The crystal structure of the autoprotease domain was, therefore, positioned 
between the small tail and the small pincher domain and oriented so that the C-terminal 
residue of the glucosyltransferase structure (Leu542) could be connected with the N-
terminal residue of the autoprotease structure (Gly547) using a short linker. 
 
pH dependent conformational changes of TcdA 
 To understand the structural basis for pore formation within the endosome, we 
analyzed TcdA particles at low pH. TcdA was applied to a carbon-coated, glow-
discharged grid, washed with a pH 4.5 buffer, and then stained with uranyl formate. This 
resulted in a clear conformational change in the toxin as shown in Figure 3-11 (compare 
with Figure 3-4C). To examine the structural homogeneity of TcdA in a low pH state, 
approximately 4,000 particles were selected from images of untilted specimens and 
classified into 10 groups. This analysis revealed a number of classes with structurally 
homogenous particles suitable for further structural analysis (Figure 3-3A). Significantly, 
although the binding domain in these classes looks similar to TcdA at neutral pH, the 
head domain clearly has undergone a major conformational rearrangement (compare 
Figure 3-11B with 3-4D). To more carefully address the structural changes in TcdA 
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structure at endosomal pH, additional images of TcdA in a low pH state were collected at 
60˚ and 0˚. 8,319 particle pairs were selected, and images from the untilted specimens 
were grouped into four classes by reference based alignment using references chosen 
from the original alignment of ~4,000 particles (Figure 3-3A, marked by *). Two of the 
resulting classes looked very similar, differing only in the orientation of the receptor-
binding domain relative to the head domain (Figure 3-5B, marked by *). One of these 
classes was used to generate a 3D reconstruction with a resolution of ~30 Å (Figure 3-
11C, and Figure 3-3C). 
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Figure 3-11. pH induced conformational changes of TcdA. TcdA was adsorbed to a 
carbon-coated glow-discharged grid, washed with 50 mM sodium citrate at pH 4.5, and 
stained with 0.7% uranyl formate. (A) A typical electron micrograph of TcdA at low pH. A 
few of the particles are circled in black. Scale bar, 500 Å. (B) A representative class 
average of negatively stained TcdA particles (1,327) at low pH. Side length of panel is 
57.3 nm. (C) The 3D reconstruction of TcdA in a low pH state is shown filtered to 30 Å.  
 
 
 The 3D structure of TcdA at low pH shows a molecule that has undergone a 
major conformational change from the structure observed at neutral pH. Although the 
conformation of the binding domain has not changed, the low pH form is more elongated 
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due to an extension in the opposite direction from the binding domain. This extended 
‘appendage’ is ~100 Å long and ~ 40 Å x ~40 Å wide at the distal end. The proximal end 
where the appendage connects to the rest of the toxin is narrower (~20 Å x 20 Å). The 
orientation of this extended appendage is relatively flexible as seen in both the class 
averages and 3D reconstructions (Figure 3-3B). 
 The low pH structure of TcdA has a volume that corresponds to a MW of ~240 
kDa and is thus considerably smaller than the structure of native TcdA whose volume 
corresponds to a MW of ~320 kDa. Since the low pH and neutral pH forms of the toxin 
look identical by SDS-PAGE (Figure 3-12A), this difference may be due to greater 
flexibility and/or partial unfolding at low pH. When comparing the neutral and low pH 
structures, it appears that much of this volume difference can be attributed to the 
glucosyltransferase domain. To investigate whether the TcdA glucosyltransferase 
domain unfolds at low pH, we purified this domain and tested its solubility in a range of 
pH conditions. At pH < 5 the glucosyltransferase domain precipitates (Figure 3-12B), 
consistent with the behavior of an unfolded protein.  
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Figure 3-12. pH dependence on the solubility of TcdA glucosyltransferase domain. 
(A) TcdA was incubated at either pH 7 or pH 4.5 for 5 minutes. The proteins were run on 
a gel and visualized by SDS-PAGE with Coomassie staining. (B) Recombinantly 
expressed glucosyltransferase domain (0.38 mg/mL) was exposed to a range of pHs, 
and the absorbance of the soluble protein was measured at 280 nm. 
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Discussion 
 
 The homology between TcdA and TcdB (68% similar, 47% identical) and the 
similar modes of entry suggest that these toxins will adopt similar three-dimensional 
structures. Although in our studies TcdB was more structurally heterogeneous than 
TcdA, both toxins clearly have a bi-lobed, globular ‘head’ domain that directly connects 
to two extended tails. Due to the similarities between TcdA and TcdB at both a structural 
and primary sequence level, we propose that, as with TcdA, the TcdB globular head 
domain represents the delivery domain, while the short tail contains the 
glucosyltransferase domain and the serpentine tail corresponds to the receptor binding 
domain. Since TcdA was considerably more homogeneous in structure, we focused our 
domain mapping and 3D structural studies on this protein. 
 The structures of TcdA holotoxin provide a framework for considering the 
molecular events required for LCT cellular intoxication. The first event is molecular 
recognition of a receptor on the surface of host cells. Studies suggest that the receptors 
for TcdA likely differ from those used by TcdB, although both toxins can bind specifically 
to carbohydrate structures containing an N-acetyl-lactosamine core (119,182,183). The 
TcdA and TcdB binding domains consist of two types of repetitive peptide sequences: 
19-22 amino acid short repeats and 31 amino acid long repeats (116). In TcdA, 32 short 
repeats are interspersed by 7 long repeats (115). Crystal structures of binding domain C-
terminal fragments have revealed that the short repeats form β-solenoid subunits that 
pack together in extended rods (115,124,172). Long repeats also form β-solenoids, but 
are packed differently yielding kinks in the rods. Each long repeat together with an 
adjacent short repeat form a binding site for the saccharide receptors (124). A model of 
the entire TcdA binding domain generated from crystallographic data and the protein 
sequence suggests an extended kinked structure that agrees well with our EM 
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observations (Figure 3-6) (115). Although a narrow, elongated structure might be 
expected to adopt multiple conformations, our EM images indicate that the domain is 
fairly rigid. This rigidity is consistent with the highly conserved packing interactions and 
regular rotational relationships observed between the long and short repeats in three 
different crystal structures of TcdA fragments. This is also reflected by the homogeneity 
of the particles and the fact that the domain structure does not change with pH. The 
structure demonstrates that the binding domain extends away from the delivery domain 
such that multiple binding sites are accessible, consistent with a model of multivalent 
binding. 
 The principle difference in the 2D images of TcdA and TcdB is that the TcdB 
density corresponding to the receptor-binding domain tail is considerably shorter, 
consistent with it being 40% shorter in its sequence. The structure of this domain is 
predicted to have four structural modules (each consisting of 3-5 short repeats and 1 
long repeat) as compared to seven in TcdA (115). Truncating the TcdA structural model 
after 4 modules results in a structure similar in length and shape to what we observe by 
EM. The density for the TcdB receptor binding domain was more difficult to observe in 
our class averages (Figure 3-2). We interpret this to mean that the TcdB receptor-
binding domain is able to adopt multiple orientations with respect to the rest of the 
molecule. This heterogeneity is the likely explanation for why the molecular envelope for 
TcdB obtained by SAXS differs from what we observe (172) since ab initio envelope 
calculations from scattering data can be problematic in flexible systems where domain 
orientations differ between conformers (184,185).  
 TcdA and TcdB have been proposed to undergo pH dependent conformational 
changes in order to form a pore through which the glucosyltransferase domain is 
translocated (128). We have directly visualized pH inducible changes in TcdA and the 
TcdA delivery domain by exposing them to low pH on EM grids. We see significant 
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changes in the pincher-like head of the delivery domain that results in its extension away 
from the binding domain (Figure 3-13 and 3-7E,F). This might be accomplished through 
a decoupling of the two lobes of the head, effectively opening the pincher.  
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Figure 3-13. Model of the conformational changes induced at low pH. 3D 
reconstruction of TcdA in a (A) neutral pH and (B) low pH state. The proposed locations 
of the functional domains are colored as follows: glucosyltransferase (red), autoprotease 
(blue), delivery (yellow) and binding (green).  
 
 
 The two-lobed pincher-like structure of the head reveals that the TcdA delivery 
domain has a complex structure, and might contain two subdomains. BLAST analysis of 
the complete TcdA delivery domain (residues 801-1831) reveals that there are two 
regions with distinct homology profiles: residues ~ 801-1400 (D1) and 1401-1831 (D2) 
(Figure 3-14) (186). TcdA D1 is more highly conserved among LCTs (55% identity with 
TcdB) than D2 (33% identity with TcdB) and contains the putative membrane spanning 
residues, suggesting that D1 is the region that rearranges to form the elongated 
appendage of the low pH form. In D2, most of the BLAST homologs are distant and 
uncharacterized, but the region is thought to enhance the binding of TcdA to cells (182) 
and contains a DSG aspartate protease motif which may be involved in toxin delivery 
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into the cytosol (134). Further study is needed to dissect the respective roles of these 
delivery domains in the context of the membrane. 
801 1301 1801
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Figure 3-14. BLAST analysis of the TcdA delivery domain. Analysis of the TcdA 
delivery domain protein sequence (residues 801-1831) using BLAST reveals two regions 
of homology. 
 
 
 Release of the glucosyltransferase domain into the cell is mediated by the 
adjacent cysteine protease domain (135). The location of the autoprotease domain 
within the map of TcdA was not experimentally determined, but the structure is 
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anticipated to be located so that the C-terminus of the glucosyltransferase domain can 
be cleaved in the active site of the protease (173). The TcdA autoprotease domain is 
known to undergo significant rearrangement upon exposure to InsP6 (173). Analysis of 
cleaved TcdA in negative stain reveals that the particles are much more heterogenous 
than those of native TcdA and impeded our efforts to obtain class averages. The 
heterogeneity of cleaved TcdA likely results from the removal of the glucosyltransferase 
domain, since this domain makes contact with the binding domain in the structure 
determined at neutral pH. It is tempting to speculate that this contact may help “lock” the 
TcdA head in a non-pore forming state, a model that is further supported by our data 
showing the glucosyltransferase domain loses structural stability at low pH.  
 In our structures of TcdA, we observed a smaller volume at low pH than in the 
neutral pH structure. We attribute this loss of volume to partial unfolding of the 
glucosyltransferase domain. The enzymatic components of anthrax toxin, botulinum 
neurotoxin, and diphtheria toxin have also been shown to unfold at low pH (187-189). In 
these toxins, which also form pores at endosomal pH, unfolding is thought to be 
necessary for translocation of the enzymatic domains through narrow membrane pores. 
In spite of this mechanistic similarity, anthrax toxin, botulinum neurotoxin, and diphtheria 
toxin have been noted for their diversity in structure (190). The unique structural features 
observed in this study, namely a bi-lobed delivery domain tethered to enzymatic cargo 
and a serpentine receptor-binding domain, suggest that TcdA and TcdB represent yet 
another structural theme for bacterial protein toxins. Further work is needed to 
understand the commonalities and differences between the TcdA and TcdB structures 
and how these structures guide the complex functions of these molecules. 
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CHAPTER IV 
 
STRUCTURAL DETERMINANTS OF THE GLUCOSYLTRANSFERASE ACTIVITY OF 
CLOSTRIDIUM DIFFICILE TOXIN A 
 
 
Introduction 
 
Although TcdA and TcdB have long been accepted as the primary virulence 
factors responsible for CDAD, there are conflicting data concerning the relative 
importance of each of the two toxins in causing disease 
(101,103,104,107,108,113,114,191). Although the roles of the toxins in human disease 
are unclear, a number of differences in activity have been noted for TcdA and TcdB in 
cells and in animal models. TcdA has been shown to be a potent enterotoxin in hamster 
and rabbit ileal loop assays, whereas TcdB is not (103,104). Both toxins are reported to 
have potent enterotoxic effects on human tissues (101,111). In cell culture, both TcdA 
and TcdB induce cell rounding, but TcdB is ~1000 times more potent than TcdA in most 
cell lines (84,192).  
The molecular basis for the observed differences in TcdA and TcdB cytopathicity 
could include differences in the binding (84), pore-forming (130), autoproteolysis (193), 
and glucosyltransferase (84) activities. Multiple studies have demonstrated that TcdA 
and TcdB have different binding activities, suggesting that the toxins have distinct 
receptors (84,119,182,183). Distinct binding targets almost certainly contribute to 
differences in potency towards various cells (84). However, in one of the few studies 
directly comparing the activities of TcdA and TcdB, Chaves-Olarte et al. have reported 
that the difference in glucosyltransferase activity was the major determinant contributing 
to the difference in cytopathic potency between TcdA and TcdB. The authors showed 
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that TcdB holotoxin (HT) is ~100 times more active than TcdA HT at targeting substrate 
in vitro. In the absence of GTPase, TcdB also had a higher rate of UDP-glucose 
hydrolysis (84).  
To understand the structural basis for the differences in glucosyltransferase 
activities of TcdA and TcdB, we have determined crystal structures of the TcdA GTD 
with and without its co-substrate UDP-glucose. We find that the enzymatic core of the 
TcdA GTD is highly similar to that of the TcdB GTD but that the GTPase recognition 
surface differs significantly. In evaluating the functional importance of divergence in 
these surfaces, we observe that both GTDs modify RhoA, Rac1, and Cdc42 at 
comparable levels in vitro, but that TcdA can also modify members of the Ras-GTPase 
family: Rap1A and Rap2A. The TcdA-mediated glucosylation of Rap2A is detected in a 
cell intoxication model, while Rap2A glucosylation is not observed in TcdB- or mock-
treated cells.  
In addition, we have compared glucosyltransferase activities of the holotoxins 
with those of the GTDs alone. We find that in the context of the holotoxin, glucosylation 
of substrates is inhibited. Activity can be restored by release of the GTD through 
autoproteolysis. We propose a model wherein the receptor-binding domain occludes the 
binding of GTPase substrates and discuss the importance of cellular activation in 
determining the array of substrates available to the toxins once delivered into the cell. 
 
Methods 
 
Plasmid construction and point mutants 
 The nucleotide sequences encoding aa 1-2710 of TcdA (TcdA holotoxin), 1-542 
of TcdA (TcdA GTD), or 1-543 of TcdB (TcdB GTD) were amplified from VPI 10463 and 
cloned into the Bacillus megaterium expression vector pC-His1622 (MoBiTec, BMEG20) 
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using the restriction sites BsrGI and SphI. The gene encoding TcdB was also cloned into 
BMEG20 as described previously (194). The GTPase sequences were cloned into 
pGEX4T (RhoA (195), Rap1A, Rap2A) or pGEX2T (Rac1 (195), Cdc42 (195)) using the 
sites BamHI and EcoRI to generate GST-GTPase fusions.  
 
Protein Expression and Purification 
 The TcdA, TcdB, TcdA GTD, and TcdB GTD plasmids were transformed into B. 
megaterium following the manufacturer’s instructions (MoBiTec). Transformed B. 
megaterium were grown in luria broth (LB) containing 10 mg/L tetracycline. 30 mL of 
overnight culture was used to inoculate 1 L of media and the cultures were placed at 
37°C and 230 rpm. When the cultures reached OD600 = 0.3, expression was induced by 
the addition of 5 g D-xylose. After 4.5 h the cells were harvested by centrifugation and 
resuspended in 100 mM NaCl, 20 mM Tris, pH 8.0. Following French Press lysis, the 
lysates were centrifuged at 48,000 g for 20 min. Protein was purified from the 
supernatant by Ni-affinity chromatography followed by gel-filtration chromatography in 
100 mM NaCl, 20 mM Tris, pH 8.  
 The GTP binding proteins were expressed in E. coli BL21 cells grown in LB 
containing 100 mg/L ampicillin. 10 mL of overnight culture was used to inoculate 1 L of 
media and the cultures were placed at 37°C and 230 rpm. When the cultures reached 
OD600 = 0.6, the temperature was changed to 21°C and expression was induced by the 
addition of 0.5 mM IPTG. After 16 h, the cells were harvested by centrifugation and 
resuspended in 100 mM NaCl, 20 mM Tris, pH 8.0. Following French Press lysis, the 
lysates were centrifuged at 48,000 g for 20 min. Protein was purified from the 
supernatant using glutathione-sepharose 4B (GE) followed by gel filtration 
chromatography. The GTPase GST tags were not removed. 
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Crystallization 
 TcdA GTD was concentrated to 16 mg/mL in 150 mM NaCl, 20 mM Tris, pH 8.0. 
TcdA GTD was crystallized by the sitting-drop method at 21°C with a 1:1 ratio of protein 
of mother liquor containing 0.2 M L-proline, 10% PEG 3350, and 0.1 M HEPES, pH 7.5. 
For co-crystallization of the GTD with substrate, 10 mM UDP-glucose and 2 mM MnCl2 
were added to the protein, and hanging drops were prepared with mother liquor 
containing 20% PEG 6000 and 0.1 M bicine, pH 8-9. Crystals were exchanged into the 
appropriate mother liquor containing either 15% glycerol (protein alone) or 20% ethylene 
glycol (protein plus UDP-glucose/Mn2+), mounted on cryo loops, and flash cooled in 
liquid nitrogen.  
 
Structure Determination and Refinement 
 X-ray data were collected from single crystals on NE-CAT beamline 24 ID-C at 
the Advanced Photon Source (Argonne, IL) at 100 K and a wavelength of 1.0094 Å. 
Diffraction data were indexed, integrated, and scaled using HKL2000 (155). A starting 
model was obtained for the TcdA GTD without UDP-glucose by molecular replacement 
with the TcdB GTD (pdb 2BVM) as a search model using Phenix. The model was 
iteratively built using Coot (157) and refined using Phenix (158) with 5 TLS groups per 
chain (Table 4-1). The structure with UDP-glucose bound was determined in the same 
way, except the apo- structure was used as the search model for molecular 
replacement. In the final structures, 90.0 and 91.2% of the residues were in the most 
favored positions in the Ramachandran plot for the bound and apo structures, 
respectively (calculated by PROCHECK (159)). No residues were in disallowed regions. 
For the apo structure the final model consists of residues 2-538, 1 manganese ion, and 
233 water molecules. For the structure with UDP-glucose bound, the final model 
consists of residues 2-538, 1 manganese, 1 UDP-glucose, and 109 water molecules. 
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Table 4-1. X-ray data collection and refinement statistics for the crystal structures 
of the TcdA GTD 
 
 TcdA GTD with UDP-
glucose 
Apo-TcdA GTD 
Data collection   
Space group P65 P65 
Cell dimensions   
    a, b, c (Å)1 141.8, 141.8, 63.4 141.9, 141.9, 66.0 
    α, β , γ (°)  90, 90, 120 90, 90, 120 
Resolution (Å) 50-2.58 (2.67-2.58) 50-2.2 (2.28-2.2) 
Rmerge2 5.7 (54.6) 5.6 (53.4) 
I / σI 21.5 (2.7) 23.4 (3.1) 
Completeness, % 99.8 (99.4) 100.0 (99.9) 
Redundancy 6.1 (5.8) 6.2 (6.0) 
   
Refinement   
Resolution, Å 40.93-2.58 48.30-2.20 
No. reflections 22,207 37,260 
Rcryst / Rfree3 17.74/24.76 18.19/22.70 
No. atoms   
    Protein 4,403 4,403 
    Ligand/ion 37 1 
    Water 109 233 
B-factors   
    Protein 48 46 
    Ligand/ion 38 99 
    Water 37 41 
Bond lengths rmsd, Å 0.007 0.007 
Bond angles rmsd, ° 1.087 1.004 
1 Values in parentheses are for highest-resolution shell. Each structure was determined using 
data from a single crystal. 
2 Rmerge =  Shkl(Si|Ihkl,i - <Ihkl>))/Shkl,i<Ihkli>, where Ihkl,i, is the intensity of an individual measurement 
of the reflection with Miller indices h, k and l, and <Ihkl> is the mean intensity of that reflection.  
3 Rcryst = S||Fobs, hkl| - |Fcalc, hkl||/|Fobs, hkl|, where |Fobs, hkl| and |Fcalc, hkl| are the observed and 
calculated structure factor amplitudes. Rfree is equivalent to Rcryst but calculated with reflections 
(5%) omitted from the refinement process. 
  
 
In vitro glucosyltransferase assay 
 UDP-[14C]glucose (250 mCi/mmol) was obtained from PerkinElmer. GTD (6.2 
nM) and GTP binding protein (2 µM) were mixed with 24 µM UDP-[14C]glucose in a 
buffer containing 50 mM HEPES, pH 7.5, 100 mM KCl, 1 mM MnCl2, 2 mM MgCl2, and 
0.1 mg/mL BSA. The total reaction volume was 10 µL. The reactions were incubated at 
  
 83         
37°C for 1 h. The reaction was stopped by the addition of loading buffer and heating, 
and the proteins were separated by SDS-PAGE. Glucosylation of GTPase was analyzed 
by phosphorimaging. For graphical representation, band densitometry was measured 
with Image J software, and the band intensities were normalized with RhoA modified by 
TcdA GTD set at 100%.  
 
In vitro autoprocessing of TcdA and TcdB 
 TcdA and TcdB (4 µM) were mixed with 10 mM InsP6 and 50 mM 
ethylenediaminetetraacetic acid (EDTA) in a buffer consisting of 100 mM NaCl, 20 mM 
Tris, pH 8. The samples were incubated 2 h at 37°C, and then dialyzed against 100 mM 
NaCl, 1mM MnCl2, 20 mM Tris, pH 8. A fraction of the samples was subjected to SDS-
PAGE (Figure 4-1) The proteins were diluted in the glucosyltransferase buffer and used 
at a final concentration of 6.2 nM. 
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Figure 4-1. Coomassie stained gel showing the GTDs, holotoxins, and cleaved 
holotoxins used to assay the glucosylation of RhoA. 
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Generation of HeLa cells expressing FLAG-Rap2A 
 Cells were cultured in DMEM supplemented with 10% FBS. Flag pLJM1 Rap2A 
(196) was obtained from Addgene. Vesicular stomatitis virus-G-pseudotyped, human 
immunodeficiency virus-1 based lentiviruses were generated in human embryonic kidney 
293 cells by cotransfection with pHCMV-G (197) and pHCMVΔR8.91 (198). After, 40 h 
the virus containing supernatant was filtered and used to transduce HeLa S3 cells in the 
presence of 8 µg/mL polybrene. Transductants were selected with 2 µg/mL puromycin 
and maintained with 0.5 µg/mL puromycin. Expression of Rap2A was confirmed by 
western blotting for FLAG.  
 
Pull down of FLAG-Rap2A 
 Cells were plated to 10 cm dishes and grown to confluency. The cells were then 
treated with buffer, TcdA (10 nM), or TcdB (10 nM) in 10 mL DMEM with 10% FBS. After 
3.5 h, the cells were washed three times with PBS and placed on ice. 1 mL lysis buffer 
(150 mM NaCl, 50 mM Tris, pH 7.5, 1% Triton X-100, 10 µL/mL protease inhibitor 
cocktail, Sigma P8340) was added to each plate for 30 minutes. Cells were scraped 
from the plates, and the lysates were clarified by centrifugation. The supernatants were 
incubated with 25 µL FLAG M2 resin (Sigma A2220) for 2.5 h at 4°C. The resin was 
washed three times with 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100. FLAG-
Rap2A was eluted at 30°C for 30 minutes with 45 µL 50 mM Tris, pH 7.5, 500 mM NaCl, 
0.5% CHAPS, 5 mg/mL FLAG peptide.  
 
Mass spectrometry 
Proteins were resolved by SDS-PAGE and visualized by Coomassie blue 
staining (SimplyBlue SafeStain, Invitrogen). Protein bands of interest were excised and 
cubed, equilibrated in 100mM NH4HCO3, reduced with DTT (1/10 volume in 100 mM 
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NH4HCO3, 37oC for 15 min), and alkylated with iodoacetamide (1/10 volume in 100 mM 
NH4HCO3, 15 min). After dehydration with acetonitrile, the gel cubes were rehydrated 
with 15 µL of 25 mM NH4HCO3 containing 0.01 µg/µL trypsin protease (Modified Trypsin-
Gold, Promega), and digestion was carried out for >2 h at 37°C. Peptides were extracted 
with 60% acetonitrile, 0.1% trifluoroacetic acid, dried by vacuum centrifugation, and 
reconstituted in 10 µL of 60% acetonitrile, 0.1% trifluoroacetic acid. 0.5 µL were applied 
to a stainless steel target and mixed with 0.5 mL of α-cyano-4-hydroxycinnamic acid 
matrix (5 mg/mL, supplemented with 1 mg/mL ammonium citrate). Matrix-assisted laser 
desorption/ionization, time-of-flight (MALDI-TOF) MS and tandem TOF/TOF MS/MS 
were carried out using a Voyager 4700 mass spectrometer (Applied Biosystems), 
operated in positive-ion reflectron mode. Each MALDI-TOF mass spectrum was 
calibrated to within 10 ppm using trypsin autolytic peptides present in the sample (m/z 
842.50, 1045.56 and 2211.10).  
 
Results 
 
Structure of the TcdA GTD 
TcdA GTD crystal structures were determined in the presence and absence of 
UDP-glucose at 2.6 Å and 2.2 Å resolution, respectively (Figure 4-2, 4-3, and Table 4-1, 
pdb 3SRZ and 3SS1). As observed in GTD structures from other LCTs, the molecule is 
composed of a core GT-A fold surrounded by multiple helical projections (150). The N-
terminal projection (Figure 4-2A) is thought to act as a membrane localization domain 
(MLD), targeting the GTD to the site of membrane-bound GTPases (152,153). The other 
projections at the top right and top left of the GTD ‘front’ (Figure 4-2A) are thought to 
contribute to GTPase substrate specificity (150). 
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Figure 4-2. Structure of the TcdA GTD. (A-C) The UDP-glucose bound TcdA GTD is 
shown with the core GT-A family fold in blue and the α-helical protrusions from the fold in 
green. The mobile 516-522 loop is in yellow, and the loop from the apo structure is 
superimposed on the structure in pink. Ser517, Trp 519, and UDP-glucose are 
represented as sticks. Panel (B) shows a close up view of the 516-522 loop and panel 
(C) corresponds to a ‘top’ view (rotated 90˚ from the ‘front’ view shown in panel (A)). 
 
 
Comparison of the apo- and UDP-glucose-bound structures shows a significant 
difference in the position of the 516-522 loop (Figure 4-2, Figure 4-3). This loop contains 
a conserved serine residue, Ser517 in TcdA, which forms a hydrogen bond with the β-
phosphate group in UDP-glucose, and a conserved tryptophan residue, Trp519 in TcdA, 
which forms a hydrogen bond to the glycosidic oxygen (Figure 4-2B and Figure 4-4). In 
the apo- structure, the loop is moved such that Trp519 is located ~10 Å away from its 
position in the UDP-glucose-bound structure. A similar conformational difference has 
been noted in a comparison of the apo- structure of C. novyi Tcnα GTD and TcdB GTD 
bound to a hydrolyzed substrate (151). As described in the mammalian 
glycosyltransferases involved in carbohydrate synthesis (199), the loop acts as a ‘lid’ 
covering the bound UDP-glucose when viewed from the ‘top’ (Figure 4-2C). 
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Figure 4-3. Comparison of the apo- and UDP-glucose bound- TcdA GTD 
structures. (A) The apo- (green) and UDP-glucose bound- (blue) structures are shown 
in stereo as ribbon diagrams. The two structures are very similar, with an rmsd of 1 Å. 
(B) A close up view of the 516-522 loop is shown with Trp519 and UDP-glucose 
represented as sticks. Trp519 forms hydrogen bonds with the glucose in the UDP-
glucose bound structure. In the apo- structure, however, Trp519 is moved ~10 Å away. 
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Figure 4-4. The coordination of UDP-glucose by the TcdA GTD in pdb 3SRZ. UDP-
glucose is shown as red sticks. Residues making hydrogen bonding contacts are shown 
in black sticks. Bond distances are shown in angstroms. Hydrophobic interactions are 
shown in orange. The image was generated by LIGPLOT (200). 
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One difference between the TcdA and TcdB GTD structures is that the UDP-
glucose is intact in the TcdA-GTD structure, whereas in the TcdB-GTD structure it is 
hydrolyzed (Figure 4-5). While consistent with previously published studies showing that 
TcdB has a higher rate of UDP-glucose hydrolysis than TcdA (84,201), the molecular 
explanation for this difference is not apparent from the structure. Because TcdA was 
previously reported to have a much lower glucosyltransferase activity than TcdB (84), we 
expected to see differences in the positions of the catalytic residues. Yet, other than the 
difference in the hydrolysis of the UDP-glucose, the enzymatic core is surprisingly similar 
between TcdA and TcdB. The residues and waters involved in UDP-binding and 
catalysis are highly conserved and the binding of UDP-glucose is nearly identical (Figure 
4-5B).  
 Although the core structures of the TcdA and TcdB GTDs are conserved (Figure 
4-5A), the surface residues of these two enzymes are highly divergent. This is 
particularly notable on the ‘front’ GTPase-binding surface adjacent to the UDP-glucose 
site (154). Amino acid changes in this region result in a significant change in the 
electrostatic properties of the surface and suggest that the TcdA and TcdB GTDs could 
have different substrate specificities within the cell (Figure 4-5C-D). In addition, there are 
significant differences in the electrostatic potential properties of the MLD. The TcdB MLD 
is markedly more charged than that of TcdA. The ‘front’ surface (as shown in Figure 4-
5C-D, left panel) is dominated by a highly basic patch, while the opposite face is almost 
entirely acidic. TcdA has a smaller basic area on the front of the MLD, and lacks the 
negatively charged patch on the back. These differences could further differentiate the 
activities of the TcdA and TcdB GTDs in cells.  
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Figure 4-5. Comparison of the TcdA and TcdB GTDs. (A) The aligned structures of 
the TcdA (blue) and TcdB (orange) GTDs are shown as backbone traces. (B) A close up 
view of the catalytic site with UDP-glucose coordinating residues shown as sticks. UDP-
glucose (light blue), UDP (light orange), and glucose (light orange) are also shown as 
sticks. Manganese ions are shown as small spheres. Although the cores of the GTDs 
are conserved, the surfaces are highly divergent (C-D). The electrostatic surface 
potentials of the (C) TcdA GTD and the (D) TcdB GTDs are shown with positively 
charged surfaces colored blue and negatively charged surfaces in red.  
 
 
Glucosyltransferase activity of the TcdA and TcdB GTDs 
 The striking differences between the TcdA and TcdB surfaces led us to perform a 
side-by-side comparison of TcdA and TcdB GTD activity against a panel of Rho and Ras 
family GTPase substrates. TcdA and TcdB GTD were incubated with purified GTPases 
in the presence of radiolabeled UDP-glucose. Transfer of glucose was detected by SDS-
PAGE followed by phosphorimaging. Surprisingly, we found that TcdA and TcdB 
glucosylated comparable amounts of RhoA, Rac1, and Cdc42 (Figure 4-6). Consistent 
with a previous report (84), we observed that TcdA could glucosylate Rap1A and Rap2A, 
whereas TcdB did not. 
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Figure 4-6. Glucosyltransferase activity of the TcdA and TcdB GTDs. (A) TcdA and 
TcdB GTDs (6.2 nM) were tested for their ability to glucosylate a panel of GTPases (2 
µM). (B) The band intensities for the representative experiment shown in (A) were 
quantified by densitometry. The means ± s. d. from four independent replicates are 
shown with TcdA in gray bars and TcdB in white bars. The data are scaled with the 
average value for RhoA modified by TcdA GTD set at 100%.  
 
 
Enhanced glucosyltransferase activity following autoprocessing 
 The highly conserved enzymatic core observed in the structure of the TcdA GTD 
provides no evidence that it is a deficient enzyme as compared to TcdB. Consistent with 
this view, our in vitro studies indicate that the GTDs of TcdA and TcdB modify similar 
amounts of RhoA, Rac1, and Cdc42.  Previous studies on the glucosyltransferase 
activity of TcdA have used only TcdA holotoxin (HT).  In cells, however, the GTD is 
released and this isolated domain is thought to traffic to the membrane where it acts on 
host GTPases (132,152). We wondered whether using GTD versus HT might result in a 
difference in activity. Therefore, we tested the ability of GTD or HT for both TcdA and 
TcdB to modify RhoA (Figure 4-7). As with the isolated GTDs, we observed similar levels 
of substrate glucosylation when the TcdA and TcdB HTs were compared to each other. 
However, for both TcdA and TcdB, the HT modified less substrate than the free GTD. 
Therefore, in the context of the HT, the glucosyltransferase activity of TcdA and TcdB is 
somehow inhibited. Consistent with this observation, we show that releasing the GTD by 
initiating in vitro autoprocessing results in enhanced substrate modification, comparable 
to that of the GTD alone (Figure 4-7, Figure 4-1).  
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Figure 4-7. Enhanced glucosyltransferase activity following release from the 
holotoxin. (A) Recombinant RhoA (2 µM) was incubated with UDP-[14C]-glucose (24 
µM) and the isolated GTD, holotoxin, or cleaved toxin of TcdA or TcdB (6.2 nM of each). 
The proteins were resolved by SDS-PAGE, and the gels were analyzed by 
phosphorimaging. (B) The band intensities were measured from three replicate 
experiments. TcdA is shown in gray bars and TcdB in white (n=3, mean ± s. d). The data 
are scaled with the average value for RhoA modified by TcdA GTD set at 100%. 
 
  
Structure of the TcdA GTD in the context of the holotoxin 
 Because the HT has a lower activity than the GTD (Figure 4-7), we sought to 
understand the structural determinants of the glucosyltransferase activity in the context 
of the holotoxin. Our lab has recently determined the structure of TcdA HT at 25 Å 
resolution using electron microscopy and random conical tilt (Figure 4-8A) (194). The 
structure contains a large bi-lobed head with two extensions. We have shown that the 
larger of these extensions contains the receptor-binding domain, and the smaller one 
contains the GTD (194). Figure 4-8 shows the EM structure of TcdA with a model of the 
TcdA receptor-binding domain (green) and the structure of the TcdA GTD (blue) placed 
into the density. The GTD fits into the map with the N-terminal MLD pointing away from 
the head and fitting into a narrower region of density. The other helical projections of the 
GTD fit into density ‘flaps’ that project toward the receptor-binding domain and provide 
confidence that the general orientation of the GTD is correct.  
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Figure 4-8. Structure of the TcdA GTD alone and in the context of the TcdA 
holotoxin structure. (A-C) The 3D reconstruction of TcdA (194) filtered to 25 Å is 
shown as a mesh surface with the crystal structure of the TcdA GTD (blue) and a model 
of the TcdA receptor-binding domain (115) (green) placed into the density. UDP-glucose 
is shown as yellow spheres. In panel (C), the model of the binding domain and the 
corresponding map density are removed. (D) Surface of the TcdA GTD shown in the 
same orientation as in panel (C). The core GT-A fold is shown in blue with the additional 
α-helical regions in green (as in Figure 4-2). The 516-522 loop is colored red, and UDP-
glucose is represented as yellow spheres. Amino acids Lys448, Gln454, Glu460, 
Arg462, and Gly471 are shown in purple. The corresponding residues in TcdB have 
been shown to be involved in substrate binding (154).  
 
 
Oriented in this way (Figure 4-8), the ‘front’ surface involved in GTPase-binding 
faces the receptor-binding domain. We predict that the presence of the receptor-binding 
domain sterically inhibits binding of GTPases in the context of the holotoxin. In addition, 
the model suggests that the ‘top’ surface containing the mobile 516-522 loop will be 
occluded by the autoprocessing domain in the context of the holotoxin. This occlusion 
could affect the position of the 516-522 loop involved in UDP glucose binding, 
hydrolysis, and transfer.  
 
Glucosylation of Rap2A in cells 
 The increased activity of TcdA and TcdB following autoprocessing highlights the 
importance of the cellular context for cellular activity. Since our in vitro assay indicated 
that Rap proteins were modified at lower levels than Rho-family proteins, we wanted to 
test whether TcdA-mediated Rap modification could occur in the context of cellular 
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intoxication. We generated a HeLa cell line that stably expresses FLAG-tagged Rap2A 
by lentiviral transduction. The cells were either mock-treated or treated with 10 nM TcdA 
or TcdB. After 3.5 h, the cells were harvested, and the Rap2A was pulled down and 
subjected to SDS-PAGE. The bands were extracted from the gel, digested with trypsin, 
and analyzed by MALDI-TOF/TOF mass spectrometry. A peptide covering Rap2A amino 
acids 32-41 (m/z 1318.60 Da) was observed for Rap pulled down from mock-treated, 
TcdA-treated, and TcdB-treated cells (Figure 4-9A-C). A related peptide (m/z 1480.65) 
was observed only for pull downs from TcdA-treated cells, consistent with glucosylation 
(+162 shift) of Thr35 (Figure 4-9B). TOF/TOF fragmentation spectra of both species 
were consistent with the predicted sequence, and mapped the site of glucosylation to 
Thr35 (Figure 4-9D-E). These results closely resembled data obtained from in vitro 
glucosylation of Rap2A (Figure 4-10). Therefore, TcdA is not only capable of 
glucosylating Rap2A in vitro, but can also glucosylate it in cells. 
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Figure 4-9. Glucosylation of Rap2A in cells treated with TcdA. (A-E) MALDI-
TOF/TOF mass spectrometry indicating the glucosylation of the peptide YDPTIEDFYR. 
(A-C) A portion of the MALDI-TOF peptide mass map (m/z 1013-1825) is shown to 
highlight the diagnostic singly-charged peptide ions at m/z 1318.60 and 1480.65 (labeled 
in bold) that represent the peptide in the native and glucosylated state, respectively. The 
m/z 1480.65 is only found in the TcdA-treated samples (B). MALDI-TOF/TOF 
fragmentation spectra are shown for the m/z 1318.60 peptide (D) and for the 
glucosylated m/z 1480.65 form (E). Labeled y-ions are denoted by cleavage brackets 
below the sequence. The y8 fragment ion that contains Thr35 is diagnostic for the 
modification, which adds 162 Da. Ions are also observed that are consistent with neutral 
loss of glucose from the y8 and M+H ions.  
  
 96         
 
Figure 4-10. Detection of Rap2A glucosylation in vitro by mass spectrometry. 
Rap2A (3.4 µM) was incubated with 1.4 µM TcdA-GTD, 1.4 µM TcdB-GTD, or buffer in 
the presence of 100 µM unlabeled UDP-glucose for 2 h at 37°C. The samples were 
analyzed by mass spectrometry. (A-E) Glucosylation of the Thr35 containing peptide 
YDPTIEDFYR by TcdA GTD is demonstrated by MALDI-TOF/TOF mass spectrometry. 
(A-C) A portion of the m/z range from 1013-1825 is shown to highlight the diagnostic 
peptides at m/z 1318.60 and 1480.65 (labeled in bold) that represent the peptide in the 
native and glucosylated state, respectively. The m/z 1480.65 that is only found in the 
TcdA-treated samples (B). MALDI-TOF/TOF fragmentation spectra are shown for the 
m/z 1318.60 peptide (D) and for the glucosylated m/z 1480.65 form (E). Labeled y-ions 
are denoted by cleavage brackets below the sequence. 
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Discussion 
 
We initiated this study with the goal of understanding differences in TcdA and 
TcdB glucosyltransferase activity and substrate specificity. The glucosylation of RhoA, 
Rac1, and Cdc42 by TcdB has been well-characterized (77,150,154,202), however, 
much less is known about TcdA and the interaction of TcdA with these substrates. One 
of the few studies directly comparing the enzymatic activities of TcdA and TcdB reports 
that TcdB is ~100x more active than TcdA at glucosylating RhoA, Rac1, and Cdc42 in 
vitro and has a higher rate of UDP-glucose hydrolysis in the absence of substrate (84). 
These studies were done with the holotoxins and not with the isolated domains that are 
released into the cell. 
Here we present crystal structures of the TcdA GTD with and without its co-
substrate UDP-glucose at 2.6 Å and 2.2 Å, respectively. Because TcdA was reported to 
have a much lower glucosyltransferase activity than TcdB (84), we expected to see 
differences in the residues involved in UDP-binding and catalysis. Yet, the structure 
reveals that these residues are highly conserved, not only in identity, but also in their 
position within the GTD (Figure 4-5B).  
The conservation of the core of the GTDs led us to reinvestigate their activity 
towards a panel of GTPase substrates. Using experimental conditions similar to those of 
previous reports, we found that TcdA and TcdB were equally active at glucosylating 
RhoA, Rac1, and Cdc42 (Figure 4-6). These results contradict the previous report that 
TcdB is 100 times more potent as an enzyme (84). We hypothesized that this difference 
might be because previous studies used HT, whereas we used isolated GTD. Upon 
testing the ability of GTD and HT to modify RhoA, we found that the glucosyltransferase 
activity is inhibited in the context of the HT. The activity of the HT can be restored 
through the initiation of autoprocessing, an InsP6-induced proteolysis event that 
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releases the GTD from the rest of the toxin (134,135). Our data indicate that TcdA and 
TcdB, in each of their three structural states, modify comparable amounts of RhoA, 
Rac1, and Cdc42. We now know that TcdB undergoes autoprocessing much more 
readily than TcdA (193), and, in our hands, TcdB is also more sensitive to degradation. 
A gel documenting the cleavage state of our reagents is included as Figure 4-1. It is 
possible that in the previous study TcdB was more active than TcdA because the GTD 
was released by proteolysis, whereas TcdA remained locked in a less active 
conformation. Our findings suggest that the ~1000 fold difference in cytopathic potency 
between TcdA and TcdB is not due to differences in the intrinsic glucosyltransferase 
activity, but is more likely due to differences in binding and/or delivery of the GTD into 
the target cell. 
Although the TcdA and TcdB GTDs were equally active in our assays towards 
RhoA, Rac1, and Cdc42, TcdA was able to glucosylate the additional substrates Rap1A 
and Rap2A. To test whether this family of substrates was modified within cells treated 
with holotoxin, we generated a stable HeLa cell line expressing FLAG tagged Rap2A. 
Following treatment with TcdA HT, we lysed the cells and pulled down Rap2A. The 
protein was digested with trypsin protease and analyzed by tandem mass spectrometry. 
We were able to confidently identify a glucosylated peptide (aa 32-41) consistent with 
modification of Thr35. Thus, TcdA is capable of modifying Ras family substrates not only 
in vitro, but also in cells. Modified Rap2A peptides were not identified in mock-treated 
samples or samples treated with TcdB. 
While TcdB and C. novyi α-toxin (Tcnα) target only Rho family substrates, TcdA 
and C. sordellii lethal toxin (TcsL) can glucosylate at least some members of both the 
Rho and Ras families. When the structures are compared, TcdA and TcsL have some 
striking similarities on the putative substrate-binding surface, most notably a large 
positively charged pocket adjacent to the UDP-glucose binding pocket (Figure 4-11).  In 
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TcdB and Tcnα, however, an acidic patch replaces this basic pocket.  It is important to 
note that these characteristics are not merely due to relatedness of the proteins.  In fact, 
the GTDs of TcdB and TcsL are more closely related (75% identity) than the GTDs of 
TcdA and TcsL (47%).  
 
 
 
Figure 4-11. The electrostatic surface potential is shown for TcdA, TcdB, TcsL, 
and Tcnα. Postively charged surfaces are shown in blue. Negatively charged surfaces 
are shown in red. The circled region marks the region corresponding to the basic pocket 
in TcdA.  
 
 
The ability of TcdA to modify Ras family substrates has important implications for 
its role in pathogenesis. Rap proteins are known to be important in the regulation of cell-
cell junctions (52).  Thus, inactivation of Rap may be important for disrupting the integrity 
of the intestinal epithelium. Other Ras family members are involved in complex pathways 
regulating cell proliferation and survival (52).  It is interesting to note that all TcdB 
sequences from the pathogenic TcdA-TcdB+ strains characterized thus far have 
mutations within the GTD that allow it to modify Ras family substrates including Rap 
(53,54). It is tempting to speculate that modification of Ras substrates by TcdA is a key 
process in CDAD, and that the mutated TcdB in TcdA-TcdB+ strains allows it fulfill the 
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role of TcdA in its absence. A more complete understanding of the glucosyltransferase 
activities of these two toxins and downstream effects of glucosylation of specific 
substrates will be essential in understanding the molecular mechanisms important in 
CDAD. 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 
As the primary virulence factors of C. difficile, TcdA and TcdB are ideal 
therapeutic targets for treatment of CDAD. While a detailed understanding of toxin action 
is needed, a model of the molecular mechanism of cellular intoxication is far from 
complete. Structural information can greatly inform the mechanistic details of protein 
function. When we initiated this study, the only structural data for TcdA and TcdB were 
X-ray crystal structures of the TcdB GTD and a fragment of the TcdA RBD (Figure 5-1). 
In my thesis work, I have determined several new and important structures including 
high-resolution structures of the TcdA autoprocessing and glucosyltransferase domains 
and low resolution structures of the TcdA holotoxin. 
In Chapter II, I have presented the 1.6 Å X-ray crystal structure of the TcdA CPD, 
which is responsible for InsP6-induced auto-processing (173). InsP6 is bound in a highly 
basic pocket that is separated from an unusual active site by a β-flap structure. 
Functional studies confirmed an intra-molecular mechanism of cleavage and highlighted 
specific residues required for InsP6-induced TcdA processing. Analysis of the structural 
and functional data in the context of sequences from similar and diverse origins revealed 
a C-terminal extension and a π-cation interaction within the β-flap that appear to be 
unique among the large clostridial cytotoxins. 
In Chapter III, I described the structures of the TcdA and TcdB holotoxins (194). I 
imaged the toxins using negative stain electron microscopy and showed that these 
molecules are similar in structure. A three-dimensional structure of TcdA was 
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determined at 24 Å by random conical tilt, and the organization of the functional domains 
was mapped within the structure. One interesting feature of the structure is an 
interaction between the N-terminal part of the GTD and the RBD. This structural 
arrangement appears to occlude glucosylation of the substrates in the HT. Moreover, in 
in vitro assays, I have observed that autoprocessing is inhibited in the HT relative to the 
autoprocessing that occurs with the CPD alone. Interdomain contacts such as the GTD-
RBD interaction may be involved in this inhibition of enzymatic activity until the 
appropriate time for activation.  
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Figure 5-1. Summary of the structural information available for TcdA and TcdB. 
 
 
The structure of the TcdA HT is important, in part, because it provides a platform 
to investigate the conformational changes involved in intoxication. One of the expected 
changes is pH-inducible pore formation. So far, no method has been developed for 
imaging the LCTs in a pore state. However, we have obtained a structure of TcdA on a 
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grid following exposure to the endosomal pH. This structure reveals a significant 
structural change in the delivery domain. These rearrangements may reflect changes 
involved in pH-inducible pore-formation. In addition, we see an apparent unfolding of a 
large part of the GTD, a step likely necessary for its translocation through a pore. These 
structures of TcdA at neutral and acidic pH provide a framework for understanding the 
complex functions of this class of toxins. 
Chapter IV describes the crystal structures of the TcdA GTD in the presence and 
absence of the co-substrate UDP-glucose. While the enzymatic core is similar to that of 
TcdB, the proposed GTPase-binding surface differs significantly. I showed that TcdA is 
comparable to TcdB in its modification of Rho-family substrates and that, unlike TcdB, 
TcdA is also capable of modifying Ras-family GTPases both in vitro and in cells. The 
glucosyltransferase activities of both toxins are reduced in the context of the holotoxin 
but can be restored with autoproteolytic activation and GTD release. Based on these 
structures, I propose a model wherein the receptor-binding domain occludes the binding 
of GTPase substrates. These studies highlight the importance of cellular activation in 
determining the array of substrates available to the toxins once delivered into the cell. 
Collectively these studies have provided considerable insight into the structure of 
these toxins, the structural response to acidic pH, the mechanisms of autoprocessing, 
and the enzymatic activity of TcdA. Still, many questions remain regarding toxin function. 
What are the receptors for TcdA and TcdB, and what cells do they target in vivo? Does 
D2 have a role in binding to host cells? What is the nature of the pore structure of the 
toxins? What structural rearrangements are necessary for the toxins to access this pore 
state? How is the GTD translocated through this pore? How is the autoprotease activity 
occluded in the HT, and when/how does it be come activated? How is the GTD localized 
to the plasma membrane, and to which parts of the membrane is it targeted? How does 
it recognize its substrates? What are the effects of modification of different subsets of 
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GTPases? Clearly, a great deal of work needs to be done to understand the action of 
these two toxins. Below, I discuss our planned and ongoing efforts to address a few of 
these questions. 
 
Future directions 
  
Determine a subnanometer resolution structure of TcdA 
 We have been able to generate the first structure of the TcdA holotoxin and learn a 
great deal about its organization by EM using negative stained particles. The use of 
negative stain, however, has a number of drawbacks such as flattening and potential 
distortion of the particles. Perhaps more importantly for our studies, it limits the 
resolution at which the structures can be determined. Using cryo-EM, we could 
significantly improve the structural resolution and visualize the atomic details of how the 
TcdA holotoxin is organized. This method traps particles in a layer of vitrified ice and is 
routinely used to generate 3D structures at subnanometer resolution. As a preliminary 
experiment, our collaborators, Yoshimasa Takizawa and Melanie Ohi, have obtained 
images of TcdA in vitreous ice (Figure 5-2). The particles appear to be in random 
orientations, and although the contrast is lower than what is seen in negative stain, we 
can clearly distinguish the ‘head’ and ‘tail’ domains in the individual particles. Using cryo-
EM, we hope to determine the structure of TcdA at < 10 Å resolution.  
 Cryo-EM is amenable to a number of gold-particle labeling techniques which are 
not possible in negative stain. By imaging toxins with labeled cysteines, we can more 
accurately determine the domain organization of the toxin. Cryo-EM will allow us, not 
only to obtain higher resolution structure of the toxin and more accurately place the 
domains, but also to assess the structural changes that occur in response to 
environmental cues such as low pH, InsP6, and reductant.  
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Figure 5-2. TcdA particles in vitreous ice, imaged by transmission EM. Grid 
preparation and image collection were done by Yoshimasa Takizawa. 
 
 
As a complementary approach, we can attempt to crystallize TcdA or TcdB 
holotoxin. When we initiated this study, we could only purify the toxins from C. difficile 
culture supernatants. This did not yield high enough amounts for large-scale 
crystallization trials. However, we can now express both toxins recombinantly with 
reasonable yields. We would not be able to assess changes in the toxin upon exposure 
to environmental cues using crystallography, as we could with EM. Nevertheless, a 
crystal structure would likely yield higher resolution information, revealing much more 
about the interdomain contacts and the parts of the toxins for which we have no high-
resolution structural information (D1 and D2).  
 
Define the molecular structure of the delivery domain 
An important gap in our current understanding of TcdA and TcdB structure is 
highlighted by the lack of structural models for the central region (Figure 5-1). This 
region has been dubbed a delivery domain based on its putative role in pore formation 
and translocation of the GTD. Our observation that this region exists as a bi-lobed 
structure has led us to consider a hypothesis wherein the central region is composed of 
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discrete structural and functional domains, D1 and D2 (203). A hydrophobic sequence 
located within D1 has been hypothesized to span the membrane during pore formation, 
and very recent studies from Genisyuerek, et al. support the idea that this region 
contains the region essential for forming pores. (131,204). To aid in determining the 
mechanism of pore-formation, I have attempted to crystallize the TcdA delivery domains, 
D1 and D2. I have cloned, expressed, and purified amino acids 799-1460 (D1) and 799-
1859 (D1-D2) in sufficient amounts for crystallization trials (Figure 5-3A). 
Preliminary experiments with the full delivery domain have yielded clusters of 
microcrystals (Figure 5-3B). Single crystals cannot be isolated from the clusters; nor 
would they be large enough to use for structure determination. However, this does show 
that the recombinant D1-D2 domain is structured and capable of crystallization. We are 
hopeful that further crystallization trials with the protein, or the corresponding protein 
from TcdB, will yield diffraction-quality crystals.  
 
 
 
Figure 5-3. Crystallization of the TcdA delivery domain. (A) The TcdA delivery 
domain (D1-2, residues 771-1859) and TcdA D1 (residues 799-1460) can be expressed 
recombinantly and purified with high yield. The purified proteins are shown by SDS-
PAGE with Coomassie blue staining. (B) Microcrystals have been generated for a ~125 
kDa protein corresponding to TcdA D1-2. (C) A construct corresponding to TcdA D1 
forms large, reproducible crystals. (D) The TcdA D1 crystals diffract to 7 Å. 
 
Large, reproducible crystals have been obtained with the TcdA-D1 protein 
(Figure 5-3C). The crystals of TcdA-D1 diffract to 7 Å (Figure 5-3D), and a complete 
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dataset has been obtained (99.8% complete overall, 96.7% complete in the highest bin). 
The data are isotropic and display no obvious crystallographic defects as analyzed by 
Phenix Xtriage (158). We could potentially determine the structure of D1 at 7 Å 
resolution using these crystals. However, it would be preferable to generate higher 
quality crystals. Thus, we will try modifying the current crystallization conditions or 
identifying alternate crystal forms.  
 
Determine the structural features of the TcdA pore 
The EM structures at neutral and low pH suggest significant structural change in 
the delivery domain, but the sequences associated with membrane insertion and pore 
formation are unknown. Genisyuerek, et al. have recently reported that the minimal pore-
forming region is contained within residues 830-990. Characterizing the pore state will 
require a method of getting a homogenous sample of the sample in the pore state in a 
lipid system. We have made preliminary attempts to prepare samples with the toxin 
inserted in liposomes. Further studies are necessary to determine whether or not the 
toxin is actually in a pore state in this system. To test for functional pores we will monitor 
the release of potassium, chloride, or fluorescent probes such as calcein from preloaded 
liposomes. 
To identify the transmembrane sequence in the pore state we plan to use a 
liposome-based protease protection assay. Toxin inserted proteoliposomes will be 
digested with protease, washed, and subjected to mass spectrometry analysis. The 
identification of extended peptides would suggest that they were protected within the 
proteoliposome. This approach has recently been used within our lab to identify regions 
of the Clostridium botulinum neurotoxin that are associated with the membrane at low 
pH (205). Mutational analysis of the residues within the protected region will be used in 
liposome-based calcein release assays to confirm their importance in pore-formation. 
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A challenging, but more revealing, objective is to obtain a structure of TcdA or 
TcdB in the pore state. To do this, we plan to work with our collaborator, Melanie Ohi, to 
obtain images of the TcdA pore in a lipid system. 2D electron crystallography has been 
used to determine the structure of many membrane proteins. We propose to generate 
2D crystals of TcdA in its pore state in planar lipid bilayers. To aid in this process, I have 
identified detergents that allow the solubilization of TcdA under low pH conditions. TcdA 
in detergent micelles will be mixed with lipids, and the detergent will be dialyzed out. 
Under the right conditions, the TcdA pores will be concentrated within the remaining lipid 
bilayers and form regular 2D arrays which can be used for structure determination. If we 
are unable to obtain 2D crystals, we will image single TcdA pores in lipid bilayers, 
monolayers, or liposomes. These methods may not yield as high of resolution 
information as 2D crystallography, but will minimally answer the important question of 
the oligomeric state of the pore. 
 
Elucidate the structural determinants of GTD-GTPases binding and specificity 
We plan to use the structure of the TcdA and TcdB GTD to elucidate the 
structural determinants that account for the difference in activity towards Rap2A. Jank, et 
al. have identified 5 TcdB residues that are involved in binding to GTPases: Glu449, 
Arg455, Asp461, Lys463, and Glu472 (154). These residues are located adjacent the 
UDP-glucose binding pocket (Figure 1-7B). Interestingly, these residues are not 
conserved between TcdA and TcdB. Divergence within these residues contribute to 
striking differences in electrostatic surface potential on the surface of the GTDs that is 
known to be involved in GTPase binding (Figure 4-5C,D). For example, Glu449 and 
Glu472 of TcdB contribute to an acidic patch just below and to the left of the UDP-
glucose binding pocket (Figure 4-11, circled). By contrast, in TcdA these residues are 
Lys448 and Gly471, and they are found in a large basic pocket. I hypothesized that this 
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basic pocket that is in TcdA but not TcdB may be involved in recognition of Rap. 
The structures of GTDs from homologous LCTs support this hypothesis. TcdB 
and Tcnα target only Rho family substrates, whereas TcdA and TcsL can glucosylate 
members of both the Rho and Ras families (Figure 4-11). When the structures are 
compared, TcdA and TcsL both have a positively charged pocket (Figure 4-11). TcdB 
and Tcnα, however, have an acidic patch. The sequences of the TcdB variants which 
modify Ras family substrates suggest that they will also have a basic pocket similar to 
TcdA and TcsL. I hypothesize that these differences contribute strongly to the different 
substrate specificities of the GTDs.  
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Figure 5-4. Residues of TcdA and TcdB that may contribute to substrate 
specificity. (A) In the TcdA GTD K448 and G471 are found in a large basic pocket. (B) 
The corresponding residues of TcdB, Glu449 and Glu472, contribute to an acidic patch. 
(C) TcdA and TcdB GTD mutants were tested for their ability to modify RhoA, Rac1, 
Cdc42, and Rap2A. Mutation of TcdA K448 or G471 to glutamate reduces glucosylation 
of Rac, Cdc42, and Rap2A. Likewise, mutation of TcdB E449 lysine reduces the potency 
towards its substrates. 
 
 
In my initial attempts to map residues involved in substrate specificity, I have 
mutated TcdA Lys448 and Gly471 to glutamate as in the corresponding protein from 
TcdB. These mutant GTDs have a decrease in their ability to modify Rac1, Cdc42, and 
Rap2A (Figure 5-4). The corresponding mutation, Glu449Lys in TcdB also decreases 
modification of substrates, particularly Rho. These experiments suggest that these 
residues are involved in binding substrates for TcdA, as has already been shown for 
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TcdB. I expected that mutation of TcdA residues to the identity of the corresponding 
residues in TcdB would specifically affect Rap modification, but instead they affected the 
interaction with multiple substrates. These results indicate that the differences in 
substrate binding between TcdA and TcdB are likely to be complex. I have generated a 
number of other mutants and combinations of mutants and chimeras to continue trying to 
define regions involved in Rap-specific substrate binding.  
In addition, we will attempt to co-crystallize the TcdA or TcdB GTD in complex 
with a target GTPase. We have the reagents necessary to prepare large amounts of the 
purified proteins necessary to begin crystallization trials. A co-crystal structure of a GTD 
and GTPase would reveal all of the residues involved in the GTD-substrate interaction 
and facilitate the elucidation of the determinants of substrate binding and specificity for 
all of the LCTs. 
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